

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
6 May 2004 (06.05.2004)

PCT

(10) International Publication Number
WO 2004/037371 A2

(51) International Patent Classification⁷:

B01D

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(21) International Application Number:

PCT/US2003/033354

(22) International Filing Date: 21 October 2003 (21.10.2003)

(25) Filling Language: English

(26) Publication Language: English

(30) Priority Data:

60/420,065 21 October 2002 (21.10.2002) US

(71) Applicant (*for all designated States except US*): JANSSEN PHARMACEUTICAL N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BARBIER, Ann, Johanna [BE/US]; 7421 Eads Avenue, La Jolla, CA 92037 (US). WILSON, Sandy, J. [US/US]; 10669 Carmel Mountain Road, San Diego, CA 92129 (US). MAZUR, Curt [US/US]; 943 Armada Terrace, San Diego, CA 92106 (US).

(74) Agents: ELDERKIN, Dianne et al.; Woodcock Washburn LLP, One Liberty Place, 46th Floor, Philadelphia, PA 19103 (US).

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ASSAY FOR DETERMINING THE ACTIVITY OF FATTY ACID AMIDE HYDROLASE

FAAH Assay



(57) Abstract: The invention provides methods of assaying fatty acid amide hydrolase (FAAH) activity adaptable for high throughput screening. The methods provide for separating a labeled substrate from at least one labeled hydrolysis product, the separation facilitating the quantification. The invention also provides methods of identifying a compound to be tested as an inhibitor or an activator of FAAH activity through the addition of the compound to be tested to a reaction mixture and comparison of the enzyme activity in the presence and absence of the compounds to be tested. The methods are adaptable for use in detecting altered FAAH activity in patients, for example, those at risk for *in vitro* fertilization failure, or at risk for, or suffering, addictions.

WO 2004/037371 A2

Assay for Determining the Activity of Fatty Acid Amide Hydrolase

Field of the Invention

The present invention relates to methods for determining the activity of and identifying modulators of fatty acid amide hydrolases. More specifically, the invention relates to an assay, adaptable for high throughput screening, for compounds that alter fatty acid amide hydrolase activity.

Background

10 The identification of anandamide (N-arachidonylethanolamine, AEA) as an endogenous ligand for the cannabinoid 1 receptor (Devane *et al.* (1992) *Science* 258:1946-1949) evoked much scientific interest in the function of bioactive lipids. Other examples of endogenous ligands are oleamide (*cis*-9,10-octadecenoamide), best known for its sleep-inducing properties (Cravatt *et al.* (1995) *Science* 268:1506-1509), and 2-arachidonoylglycerol, reported to be neuroprotective after brain injury (Panikashvili *et al.* (2001) *Nature* 413:527-531).

15 The main mechanism for the termination of the biological activity of anandamide is hydrolysis (Giuffrida *et al.* (2001) *J. Pharmacol. Expt. Ther.* 298:7-14); the existence of an anandamide transporter has also been proposed (Compton and Martin (1997) *J. Pharmacol. Expt. Ther.* 263:1138-1143).

20 The enzyme responsible for the hydrolysis of anandamide, oleamide and 2-arachidonoylglycerol was cloned in 1996 and named fatty acid amide hydrolase, or FAAH (Cravatt *et al.* (1996) *Nature* 384:87-87). FAAH (EC 3.5.1.4) is a membrane-bound enzyme with broad substrate specificity which is expressed in a wide variety of

human tissues and cell lines (for review see Ueda *et al.*, *Chem.Phys.Lipids.* 108: 107-121, (2000); Fowler *et al.*, *Biochem. Pharmacol.* 62: 517-526, (2001)).

Inhibitors of FAAH have been predicted to potentiate the effects of the endogenous cannabinoids and thereby promote sleep, muscle relaxation and analgesia 5 (Fowler *et al.* (2001) *Biochem. Pharmacol.* 62:517-526). Efforts to identify useful inhibitors have been hampered by the lack of simple, reproducible assays suitable for high-throughput screening. Published methods include reversed phase HPLC (9) and thin-layer chromatography (Deutsch and Chin (1993) *Biochem. Pharmacol.* 46:791-796). A fluorescence displacement method has also been described (Thumser *et al.* 10 (1997) *Biochem. Pharmacol.* 53:433-437). An additional assay relies on extraction of the hydrolysis product with a chloroform: methanol mixture (Maurelli *et al.* (1995) *FEBS Lett.* 377:82-86), followed by counting of radioactivity. However, the toxicity of the chloroform and the cumbersome physical manipulations of this method preclude the adaptation of this assay to a high-throughput format.

15 There is a need in the art, therefore, for improved FAAH assays, particularly those which can be adapted to high throughput screening, for determining the activity of FAAH and for identifying modulators of FAAH.

SUMMARY OF THE INVENTION

20 In one aspect, the instant invention provides methods for assaying the activity and amount of fatty acid amide hydrolase (FAAH) based on differences in the physicochemical and binding properties of a FAAH substrate, and the products of its hydrolysis. For example, anandamide is hydrolyzed by FAAH to arachidonic acid and ethanolamine (Fig. 1). In brief, a substrate, for example ^3H -anandamide 25 (ethanolamine 1- ^3H), is incubated with a putative source of FAAH activity in a

reaction mixture. The FAAH activity, where present, catalyzes the hydrolysis of the substrate to form at least one radiolabeled hydrolysis product; the example substrate ³H-anandamide is converted to labeled ethanolamine and unlabeled arachidonic acid. This labeled product and the labeled substrate are separated from each other and the 5 loss of labeled substrate, or preferably, the formation of labeled product, is measured. In certain preferred embodiments, the assays are performed in parallel or in sets wherein assays conducted in the presence of compounds to be tested for their ability to modulate the FAAH activity are compared with those conducted in the absence of the compounds to be tested. In other preferred embodiments samples from patients 10 can be assayed to determine if the FAAH activity is altered relative to a predetermined activity value.

In one aspect, the invention provides improved methods of measuring fatty acid amide hydrolase activity comprising combining a sample suspected of containing fatty acid amide hydrolase, with a labeled substrate of fatty acid amide hydrolase to 15 form a reaction mixture; incubating the reaction mixture under conditions which allow the fatty acid amide hydrolase to hydrolyze the labeled substrate, thereby forming at least one labeled hydrolysis product; contacting the incubated reaction mixture with a selective binding material wherein the selective binding material binds either the labeled substrate or the labeled product, but not both, thereby forming a 20 bound labeled complex; separating the bound labeled complex from the unbound labeled compound, thereby effectuating a separation of the labeled substrate from labeled product; and determining the amount of labeled substrate hydrolyzed or the amount of labeled hydrolysis product formed; thereby indicating the fatty acid amide hydrolase activity of the sample.

In another aspect of the invention, methods are provided for identifying compounds which can modulate the activity of a FAAH enzyme. The methods comprise the steps of comparing the activity of a FAAH as assayed by the above method in the presence and in the absence of a test compound added to the reaction mixture; wherein a change in the activity of the fatty acid amide hydrolase indicates that the test compound modulates the activity of the fatty acid amide hydrolase. In various embodiments, the methods can be used to identify useful inhibitors or enhancers of FAAH activity.

The assay methods provided herein are adaptable for use in high throughput screening systems and are contemplated to be used in drug discovery efforts. High throughput screening using the assay methods of the present invention will allow libraries of test compounds (for example, libraries produced by techniques of combinatorial chemistry) to be used in rational screening programs to identify inhibitors and enhancers of FAAH activity which are useful as candidates for drugs

In another aspect, the invention provides methods of determining altered FAAH activity in a patient. The methods comprise the steps of obtaining a sample containing cells from the patient; lysing the cells to form a cell lysate; combining the cell lysate with a labeled substrate of the fatty acid amide hydrolase, to form a reaction mixture; incubating the reaction mixture under conditions sufficient to allow a fatty acid amide hydrolase present in the cell lysate to hydrolyze the labeled substrate, thereby forming at least one labeled hydrolysis product; contacting the incubated reaction mixture with a selective binding material; wherein the selective binding material binds either the labeled substrate or a labeled hydrolysis product, but not both, thereby forming a bound labeled complex; separating the bound labeled complex from the unbound labeled compound, thereby effectuating a separation of the

labeled substrate from labeled product; determining an amount of labeled substrate hydrolyzed, or labeled hydrolysis product formed, thereby indicating the fatty acid amide hydrolase activity of the sample; and comparing the activity of the sample from the patient with a predetermined value for activity, to determine if the patient has
5 altered fatty acid amide hydrolase activity relative to the predetermined value for activity.

These and other aspects of the present invention will be described in further detail in the Detailed Description set forth below.

10 BRIEF DESCRIPTION OF THE FIGURES

Figure 1: Schematic diagram of a FAAH assay. The FAAH activity in T84 membranes converts anandamide [1-³H-ethanolamine] into radiolabeled ethanolamine and unlabeled arachidonic acid. The labeled anandamide and unlabeled arachidonic acid are selectively bound to charcoal in filterplates, whereas the
15 radiolabeled ethanolamine is collected in the flow-through and counted.

Figure 2 depicts an embodiment of a FAAH assay method. The reaction takes place in a reaction plate at room temperature. After 60 minutes, 60 µl of the reaction mixture is transferred to a charcoal-filled filter plate. The filter plate is fitted on top of a Dynex plate; the assembly is then centrifuged for 5 minutes at 2000 rpm.

Figure 3: Arachidonic acid and anandamide, but not ethanolamine, bind to activated charcoal. Four different radiolabeled tracers were used: anandamide [1-³H-ethanolamine], anandamide [arachidonyl-5,6,8,9,11,12,14,15-³H], arachidonic acid [5,6,8,9,11,12,14,15-³H (N)] and ethanolamine ([2-¹⁴C] ethan-1-ol-2-amine hydrochloride). The tracers were incubated with membranes prepared from mouse
25 liver, T84 cells, HeLa cells or with vehicle, for 60 minutes at room temperature. The

percentage (calculated from the average of triplicate determinations \pm Standard Error of the mean (s.e.m.)) of total radioactivity recovered in the flow-through is shown.

Figures 4A-4B: Characterization of a preferred assay. A: Time-course of hydrolysis of ^3H -anandamide by FAAH at room temperature and at 37°C . The 5 average of triplicate determinations \pm s.e.m. is shown. B: Determination of K_m for FAAH. T84 cell membranes (3.5 μg protein per well) were incubated with a range of concentrations of ^3H -anandamide. The reactions were carried out at room temperature in the presence or absence of inhibitors (either oleyl trimethylfluoro ketone (OTFMK) or methyl arachidonyl fluorophosphate (MAFP)). The experiment 10 where oleyl trimethylfluoro ketone was used to determine nonspecific binding is shown; the results with MAFP were comparable. Each point reflects the average of triplicate determinations \pm s.e.m.

DETAILED DESCRIPTION OF THE INVENTION

The reference works, patents, patent applications, and scientific literature, 15 including sequences denoted by their accession numbers (e.g. accession numbers to GenBank database sequences), that are referred to herein are hereby incorporated by reference in their entireties.

Various definitions are used throughout this document. Most words have the meaning that would be attributed to those words by one skilled in the art. Words 20 specifically defined either below or elsewhere in this document have the meaning provided in the context of the present invention as a whole, and as are typically understood by those skilled in the art. Where possible undefined words should be understood to have the usual meaning to the skilled artisan. Any conflict however between an art-understood definition of a word or phrase and a definition of the word

or phrase as specifically taught in this specification shall be resolved in favor of the latter.

Standard reference works setting forth the general principles of recombinant DNA technology known to those of skill in the art include Ausubel *et al.*, Current Protocols in Molecular Biology, John Wiley & Sons, New York (2002); Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Plainview, New York (2001); Kaufman *et al.*, Eds., Handbook of Molecular and Cellular Methods in Biology and Medicine, CRC Press, Boca Raton (1995).

As used herein, a "label" is a composition detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radioisotopes and fluorescent labels. Examples of radioisotopes that may be used in the method of the invention include ³H and ¹⁴C.

As used herein, "purified" refers to at least partial separation of a molecule from other molecules with which it is normally associated. For example, a purified protein is a protein that is at least partially separated from other cellular material with which it is normally associated.

As used herein, the term "murine" means originating in a member of the family *Muridae*. A murine FAAH preferably originates in a mouse, or rat.

In a first aspect the invention provides methods of assaying a fatty acid amide hydrolase (FAAH). In a presently preferred embodiment, the method of assay comprises the steps of combining a sample suspected of containing a FAAH with a labeled substrate of FAAH to form a reaction; incubating the reaction mixture under conditions sufficient to allow the fatty acid amide hydrolase to hydrolyze the labeled substrate, forming one or more labeled hydrolysis products; contacting the incubated reaction mixture with a selective binding material; wherein the selective binding

material binds either the labeled substrate or a labeled hydrolysis product, but not both, to form a bound labeled complex; separating the bound labeled complex from the unbound labeled compound, thereby effectuating a separation of the labeled substrate from labeled product; and determining an amount of labeled substrate

5 hydrolyzed, or labeled hydrolysis product formed, thereby indicating the fatty acid amide hydrolase activity of the sample.

The sample, in preferred embodiments, is a biological sample, or a sample comprising biological material, in particular biological membranes. In other preferred embodiments, the sample is from a purification step in the purification of FAAH from

10 a biological source. The sample comprises biological membranes or portions thereof, or comprises lipid bilayers, or artificial membrane systems, monolayers, vesicles or micelles. A sample in some embodiments comprises a purified or recombinant FAAH reconstituted into a phospholipid-containing reaction mixture.

The substrate may be any substrate, putative substrate, or substrate analog of

15 FAAH. The assay is also adapted for use to determine the utility of a compound as a substrate of FAAH. Substrates preferred for use in various embodiments of the present invention include, but are not limited to endocannabinoids or analogs thereof, fatty acid ethanolamides or analogs thereof, fatty acid primary amides or analogs thereof, and analogs of any of the foregoing labeled with a detectable label. Presently

20 preferred substrates of particular interest include, for example, anandamide, oleamide, and 2-arachidonoylglycerol.

The substrate may be radioisotopically labeled in any manner known in the art for labeling compounds for detection. Presently preferred isotopes, such as ³H or ¹⁴C, are readily detected via liquid scintillation counting and can facilitate adaptation of

the assays for high throughput drug screening. Synthetic substrates so labeled are readily available commercially or can be synthesized.

Other labels such as fluorescent labels capable of detection, for example fluorimetric detection, are also readily adapted to high throughput screening.

- 5 Preferred fluorescent labels are detectable in biological systems with both proteins and nucleic acids present, therefore preferred labels when assaying cruder cell lysates and homogenates possess both excitation and emission optima which are not masked by these other biological components. In one embodiment the unhydrolyzed labeled substrate has identical fluorescent properties with the hydrolysis product. It is also
10 possible to design substrates wherein hydrolysis results in a change in fluorescence, for example, where a dye-dye interaction in the unhydrolyzed molecule is required to maintain a ground state. Such substrates are useful in conjunction with the present invention. Colorimetric labels are also contemplated for use herein. Generally,
15 appropriate labels are those which do not alter the substrate's susceptibility to hydrolysis by the enzyme and for which detection systems have been developed.

Preferably the substrate is present at concentrations at vast excess relative to the concentration of the enzyme. Under such conditions classical enzyme kinetics can be used to determine a rate constant (K_m) and a velocity (V_{max}) of the reaction.

- Kinetic studies are useful for mechanistic studies; they are also powerful tools for
20 evaluating inhibitors (see below). Standard texts directed at those skilled in the art of enzyme kinetics such as Segel, I.H., *Enzyme Kinetics : Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems* (1993, Wiley-Interscience, ISBN 0471303097) provide complete guidance to establishing these parameters and demonstrate the use, for example, of Lineweaver-Burke plots as graphical tools to
25 simplify the determination of the kinetic parameters.

High throughput screening systems are known in the art. Such systems often involve the use of multiwell plates to increase the number of assays conducted simultaneously from a few to a hundred, a few hundred or even a few thousand.

Presently preferred high throughput screening adaptions of the methods of the present

5 invention provide capability of screening about one hundred to about one or more thousand assays in a short time. Presently preferred high throughput screening systems include robotic components for example for sample handling, dispensing, reagent addition, and other functions to improve accuracy and eliminate the labor intensive aspects of large numbers of assays. Detection systems for high throughput

10 screening programs are known to those of ordinary skill in the art. Preferred detection systems include, but are not limited to, scintillation counting (including, for example, solid and liquid scintillation for counting gamma or beta particles, or luminescent samples, filter counting, Cerenkov counting, and scintillating microplate counting), fluorescence detection (including, for example, intensity, fluorescence polarization, time-resolved fluorescence, fluorescence resonance energy transfer (FRET)),

15 luminescence, and absorbance.

In a presently preferred embodiment, to achieve high-throughput screening, samples are placed on a multicontainer carrier or platform. A multicontainer carrier facilitates measuring reactions of a plurality of candidate compounds simultaneously.

20 For illustration purposes, but not by way of limitation, a multi-well microplate, such as a 96 or a 384 well microplate, that can accommodate 96 or 384 different test reactions, is used as the carrier. Such multi-well microplates, and methods for their use in numerous assays, are both known in the art and commercially available through sources such as Sigma Chemical Co., BIOCHEMICAL ORGANIC COMPOUND AND

25 DIAGNOSTIC REAGENTS, 2002, pages 2495-2511.

The methods of the present invention are adaptable to miniaturization techniques. Assays for purposes of high throughput screening are often conducted in small volumes. Procedures are currently known to those of skill in the art of reducing volumes of assays in a variety of ways. Microfluidics and microcapillary methodologies now enable assays to be performed down to nanoliter quantities. It is to be understood that the basic principles of the methods and assays apply notwithstanding the volume of the assay, or the manner in which the materials are measured or transported.

The process of determining incubation conditions is routine in the art.

Preferred incubation conditions relate, for example, to enzyme stability. Temperature optiums are routine to determine given the specification of the assay and should be determined for a given enzyme and substrate combination for optimum results. Times and other conditions for incubation involve likewise routine determinations. Preference is given to those conditions which result in linearity of the assay.

Presently preferred temperatures and times include room temperature for 1 hour, or 37 °C for 30 min, using FAAH from a variety of sources and using anadamide as a substrate. Standard texts directed at those skilled in the art of enzyme assays such as Segel, *supra*, provide complete guidance to optimizing assays, including the incubation conditions. Further characterization of the preferred embodiments is provided in the working examples.

The methods also comprise a step wherein the incubated reaction mixture is contacted with a selective binding material. It is important to note that the selective binding material preferred for this assay may vary with the substrate selected. The selective binding materials comprise materials which can readily be separated from the bulk reaction mixture by separation techniques which are known in the art.

Effective separations can be based on differences in particle size, density, composition and magnetic susceptibility. Material is separated from a reaction mixture by, for example, gravity settling, filtration (including, for example, membrane separations), centrifugation, A presently preferred method of contacting the incubated 5 reaction mixture with a selective binding material comprises activated charcoal.

Where the substrate is anandamide, for example, activated charcoal binds, through adsorption, the substrate and one of the hydrolysis products, arachidonic acid. The other hydrolysis product, ethanolamine, does not adsorb to the activated charcoal. For preferred embodiments, the anandamide substrate is labeled on the ethanolamine 10 moiety. The FAAH hydrolyzes the labeled anandamide into labeled ethanolamine and unlabeled arachidonic acid. After adsorption of the labeled substrate and the unlabeled arachidonic acid to the charcoal, the labeled ethanolamine in solution can be separated from the bound labeled substrate through a simple filtration step. This facilitates the measurement of product without interference from substrate. By 15 removing some compounds through the binding process, the sample is less likely to interfere, for example by quenching, with the measurement of the labeled product. Existing technology has already been adapted for filtering large numbers of samples simultaneously, for example in multiwell filters. This attribute also is adaptable therefore to high throughput screening programs.

20 Although it is often preferred to measure the formation of product in the methods of this invention, assay conditions and selective binding material may be selected wherein the disappearance of substrate is measured. This indirect method is adaptable particularly where a partially purified or substantially purified enzyme is used, or where it is known that there is only one route by which substrate disappears 25 from the reaction mixture. It is also preferred to measure substrate disappearance

wherein a selective binding material which binds the substrate is not readily available. This can be useful in particular in embodiments where the substrate cannot practically be bound to effect its separation from free hydrolysis product but where the hydrolysis product can be more readily bound to effectively separate it from the 5 free labeled substrate. This gives a practitioner the flexibility to choose from a broader range of selective binding materials.

The determination of the amount of labeled substrate hydrolyzed or the labeled hydrolysis product formed is preferably a direct method of quantitating the amount of label present. As discussed above, a variety of detection techniques are 10 suitable for the present invention, and an appropriate detection method relates to the properties of the label present on the substrate or the product. Presently preferred for use with the methods of the invention are radioisotopically labeled substrates and fluorescently labeled substrates, quantified respectively by scintillation counting and fluorescence detection, respectively. In one preferred embodiment, the substrate is 15 ^3H -anandamide, the detection is of the product, ^3H -ethanolamine, formed, and the detection is with a liquid scintillation counting plate reader from the filtrate of an assay conducted in a multiwell plate.

In another aspect of the invention, methods are provided for identifying modulators of fatty acid amide hydrolase. The methods comprise comparing the 20 activity of fatty acid amide hydrolase as assayed by the method as described herein above, in the presence and in the absence of a test compound added to the reaction mixture; a change in the activity of the fatty acid amide hydrolase indicates that the test compound modulates the activity of the fatty acid amide hydrolase.

In preferred embodiments, the modulator to be identified is part of compound 25 library, for example, a library of compounds formed by combinatorial chemistry, or a

library of related compounds identified or synthesized as part of a research program.

The putative modulators (i.e the compounds to be tested, test compounds) are preferably a small molecule with properties that would allow it to have utility for pharmaceutical compositions. Preferred modulators have low nonspecific toxicity, 5 and high specificity for modulating FAAH.

Modulators include inhibitors of FAAH activity and activators of FAAH.

Assay parameters such as concentration of substrate, incubation conditions, and concentration of compounds to be tested may be varied to more fully appreciate the modulation effects of a test compound.

10 Preferred modulators that are inhibitors can be identified by their ability to decrease the activity of FAAH relative to that of a control reaction mixture lacking the test compound. Preferably, reaction volumes are maintained constant by adjusting the volume to compensate for the addition of a test compound where the addition of a test compound alters the reaction volume. Most preferably any difference in volume is 15 compensated for by a corresponding addition of a volume, equal to the difference, of the vehicle in which the test compounds are dissolved.

In one aspect of the invention, the modulator identified is an inhibitor of the FAAH activity. Enzyme inhibitors include reversible and irreversible inhibitors.

Preferred inhibitors in some embodiments are reversible inhibitors. Reversible 20 inhibitors of FAAH include competitive inhibitors, which raise the apparent K_m of the reaction, noncompetitive inhibitors, which reduce the V_{max} of the enzyme, and inhibitors which affect both K_m and V_{max} , namely, mixed inhibitors and uncompetitive inhibitors. The type of inhibitor identified in screens can be determined through the use of kinetic assay studies according to the methods of the present invention. For the 25 purposes of the present invention, however, any compound which decreases the

apparent activity of the enzyme is considered a modulator of the inhibitor type. In other preferred embodiments inhibiting modulators include irreversible inhibitors as well as noncompetitive inhibitors, whose action may be irreversible.

In preferred embodiments the test compound inhibits the FAAH reproducibly,
5 as determined by a statistically significant difference by an appropriate statistical test. Such tests are known to those of skill in the art of statistical determinations in scientific measurements, such as those of biological or biochemical systems. In some embodiments, the test compound inhibits fatty acid amide hydrolase activity about 1%, or at least about 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%,
10 or 90%, or about 95% or more, or up to 100%. In other preferred embodiments, the inhibitor statistically significantly increases the apparent K_m or decreases the V_{max} of the reaction.

In another aspect of the invention, the test compound increases fatty acid amide hydrolase activity. Various types of enzyme activators are known to those of skill in the art. Some activators are known to activate enzyme reactions by increasing the velocity of the reaction, others are known to alter the equilibrium attained. Activators that combine reversibly with enzyme reaction components (for example, the enzyme, the substrate, or enzyme-substrate or enzyme-product intermediates) to increase the velocity of the reaction are presently preferred. Nonspecific activators
15 may also increase the reaction rate. For purposes of the present invention, any compound that increases the apparent activity of the enzyme is considered a modulator of the activator type. For example many enzymes are known to have increased activity in the presence of certain anions. Other enzymes, in particular those acting on water-insoluble and charge-neutral molecules, are activated by
20

negatively charged lipophilic molecules. Some membrane bound enzymes are known to be activated, for example, by specific phospholipids.

In preferred embodiments the test compound activates the FAAH reproducibly, as determined by a statistically significant difference by an appropriate 5 statistical test. Such tests are known to those of skill in the art of statistical determinations in scientific measurements, such as those of biological or biochemical systems. In some embodiments, fatty acid amide hydrolase activity is increased about 1%, or at least about 2%, 3%, 4%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90%, or about 95% or more, or up to 100%. In other embodiments, activation is 10- 10 30%, 30-50%, 50-70%, 70-90%, 90-110%. In some embodiments, the activator increases FAAH activity 100-300%, 300-500%, 500-700%, or 700-900% or more.

In certain preferred embodiments of the methods of the invention, the fatty acid amide hydrolase is a crude cell lysate or a cell homogenate. In some 15 embodiments the FAAH is isolated partially or substantially from cells. In other embodiments, the fatty acid amide hydrolase is recombinantly produced. The fatty acid amide hydrolase may be from any biological source including mammalian fatty acid amide hydrolases from such animals as pigs, rodents (including rats and mice), and humans, or it may be recombinant FAAH produced in any organism known to be useful for the production of recombinant proteins. Synthetic FAAH based on a 20 particular known amino acid sequence, or on a consensus or combination of any number of sequences that result in an active FAAH is also contemplated for use herein.

Examples of known amino acid sequences of fatty acid amide hydrolases from various biological sources include, for example, SEQ ID NOS: 2, 4, 6, and 8. 25 Examples of known nucleic acid sequences encoding fatty acid amide hydrolases

include SEQ ID NOS:1, 3, 5 and 7. Persons of ordinary skill in the art will recognize that such sequences and the modifications thereof which retain activity, can be used in accordance with the techniques found in references such as those provided above to generate, for example, biological FAAH, recombinant FAAH, overproduced FAAH, 5 or genetically modified FAAH. It is contemplated herein that any form of FAAH is adapted for assay with the methods of the present invention.

In a preferred embodiment the assay is used to measure the activity and identify modulators of FAAH with altered amino acid sequences. Such altered FAAH can result from mutations in the genes which encode FAAH enzymes. In one 10 embodiment, the assay is used to study the activity of, and identify modulators of, altered FAAH in connection with cannabis abuse. For example, a recent paper by Sipe *et al.* (PNAS 99:8394-8398, 2002) describes a strong association between the substitution of Thr for Pro at position 129, and substance abuse in humans. The use 15 of the assay of the present invention may help identify FAAH from humans with higher specific activities or higher levels of net activity, thereby resulting in reduced concentrations of endocannabinoids in the brain, thereby leading to a tendency to seek external cannabinoids to compensate.

In another aspect, the invention provides methods of determining altered FAAH activity in a patient. The methods comprise the steps of obtaining a sample 20 containing cells from the patient; lysing the cells to form a cell lysate; combining the cell lysate with a labeled substrate of the fatty acid amide hydrolase, to form a reaction mixture; incubating the reaction mixture under conditions sufficient to allow a fatty acid amide hydrolase present in the cell lysate to hydrolyze the labeled substrate, thereby forming at least one labeled hydrolysis product; contacting the 25 incubated reaction mixture with a selective binding material; wherein the selective

binding material binds either the labeled substrate or a labeled hydrolysis product, but not both, thereby forming a bound labeled complex; separating the bound labeled complex from the unbound labeled compound, thereby effectuating a separation of the labeled substrate from labeled product; determining an amount of labeled substrate hydrolyzed, or labeled hydrolysis product formed, thereby indicating the fatty acid amide hydrolase activity of the sample; and comparing the activity of the sample from the patient with a predetermined value for activity, to determine if the patient has altered fatty acid amide hydrolase activity relative to the predetermined value for activity.

10 Preferably, the fatty acid amide hydrolase activity from a sample of fluid or tissue originating from the patient is measured. Presently preferred are blood, lymph or tissue samples. In particularly preferred embodiments, the sample is from lymphocytes from the patient. In preferred embodiments, where the sample is from a woman, the results enable a physician to screen pregnant women for risk of miscarriage (spontaneous abortion) or to screen women seeking fertility treatment for risk of failure of *in vitro* fertilization procedures. In preferred embodiments, results from the patient's sample are compared to results from samples of normal individuals, particularly those comparably positioned in terms of demographic criteria. Results of the assays of the present method may be used to determine either or both of altered specific activity (FAAH activity per unit of FAAH mass) or altered total FAAH activity (net amount of product formed per time). For example, increases in activity can be due to increases in specific activity of the FAAH, for example by alteration of the active site via amino acid alteration, gene mutation and the like, or through alteration of the total amount of FAAH protein present, without a change in the specific activity.

15

20

25

In the methods of the invention, the fatty acid amide hydrolase may be substantially purified from the lymphocyte cell lysate. FAAH may be derived from any source, such that the FAAH retains the potential for FAAH activity. For example, FAAH may be purified from cells expressing FAAH, FAAH may be 5 produced in a recombinant system, including, but not limited to bacterial cells, yeast cells, insect cells, and mammalian cells. FAAH may be derived from any organism that produces FAAH. For example, FAAH may be derived from mammalian cells such as human cells, rodent cells (*e.g.*, mouse and rat cells), or from any other organism that produces FAAH that has FAAH activity. Recombinant FAAH may be 10 produced using techniques known in the art with any nucleic acid sequence encoding FAAH. Examples of cloned FAAHs include various mammalian FAAH such as, pig FAAH, rodent FAAH (*e.g.*, mouse FAAH and rat FAAH), and human FAAH. DNA sequences encoding FAAH and polypeptide sequences of various FAAHs are included in the appended Sequence Listing.

15 FAAH may be purified by standard methods in the art. The FAAH preparation may be in association with cell membranes or artificial membranes, or may be substantially free of cellular material.

Throughout the specification, reference is made to certain publications and 20 patents. The entireties of each of these references is incorporated herein and forms a part of this disclosure.

EXAMPLES**Example 1**

Radiolabeled anandamide [$1\text{-}^3\text{H}$ -ethanolamine] was obtained from American Radiolabeled Chemicals (10-20 Ci/mmol, catalog number ARC-626; St. Louis, Missouri, USA). Anandamide [arachidonyl-5,6,8,9,11,12,14,15- ^3H] was obtained from Perkin Elmer (160-240 Ci/mmol, catalog number NET-1073, Boston, Massachussets, USA), as was radiolabeled arachidonic acid [5,6,8,9,11,12,14,15- ^3H (N)] (180-240 Ci/mmol, catalog number NET298Z). Radiolabeled ethanolamine ([2- ^{14}C]Ethan-1-ol-2-amine hydrochloride) was purchased from Amersham Pharmacia Biotech (55 mCi/mmol, catalog number CFA329). Methyl arachidonyl fluorophosphate (MAFP) and oleyl trifluoromethyl ketone (OTFMK) were obtained from Cayman Chemical, (Catalog number 70660 and 6260, respectively; Ann Arbor, Michigan, USA). Activated charcoal was from Aldrich Chemical, Milwaukee, USA. Arachidonic acid, anandamide, oleic acid, oleamide, phenylmethylsulfonyl fluoride and CuSO₄ were from Sigma, St. Louis, Missouri, USA.

T84 human colorectal carcinoma cells (catalog number CCL-248, American Tissue Culture Collection, Manassas, Virginia, USA) were identified as expressing human FAAH based on gene expression profiling of cell lines using DNA microchips (not shown). The cells were cultured in a 1:1 mixture of Ham's F-12 media and Dulbecco's Modified Eagle Medium (Invitrogen) with 5 % fetal bovine serum (HyClone), 50U/ml penicillin and 50 μg /ml streptomycin (Invitrogen). The cells were harvested by scraping into PBS and pelleted in a clinical centrifuge at 1000 rpm. The resulting pellets were then stored at -80°C until needed.

T84 frozen pellets were homogenized in FAAH assay buffer (125mM Tris, 25 1mM EDTA, 0.2% Glycerol, 0.02% Triton X-100, 0.4mM Hepes, pH 9) (Boger *et al.*

(2000) *Proc. Natl. Acad. Sci. USA* 97:5044-5049) and diluted to a final protein concentration of 70 µg/ml. Unless otherwise indicated, the assay mixture consisted of 50 µl of the cell homogenate, 10 µl of the appropriate inhibitor, and 40 µl of 40 nM 3 H-AEA, added last, for a final tracer concentration of 16 nM. The reactions were 5 originally done at 37°C for 30 min; but subsequent experiments indicated that the enzyme displayed good activity at room temperature, and experiments were performed at room temperature for 60 minutes unless otherwise indicated.

During the one hour incubation, 96-well Multiscreen filter plates (catalog number MAFCNOB50; Millipore, Bedford, Massachusetts, USA) were loaded with 10 25 µl activated charcoal (Multiscreen column loader, catalog number MACL09625, Millipore) and washed once with 100 µl methanol. Also during the incubation, 96-well DYNEX MicroLite plates (catalog number NL510410) were loaded with 100 µl MicroScint40 (catalog number 6013641, Packard Bioscience, Meriden, Connecticut, USA). After the one hour incubation, 60 µl of the reaction mix was transferred to the 15 charcoal plates, which were then assembled on top of the DYNEX plates using Centrifuge Alignment Frames (catalog number MACF09604, Millipore). The unbound labeled ethanolamine was centrifuged through to the bottom plate (5 min at 2,000 rpm), which was preloaded with the scintillant, as described above. The plates were sealed and left at room temperature for 1 hour before counting on a Hewlett 20 Packard TopCount. For determination of K_m values, 1 µM 3 H-AEA was combined with 30 µM unlabeled AEA and serial 2-fold dilutions were made.

Uncleaved 3 H-anandamide, as well as the unlabeled arachidonic acid, is absorbed by the charcoal. In contrast, the labeled 3 H- ethanolamine flows through the charcoal mini-columns into 96 well counting plates when a vacuum or centrifugation

is applied. The 96 well plates can then be read on a Hewlett Packard TopCount (Fig.2.)

5 *Charcoal selectively binds anandamide and arachidonic acid, but not ethanolamine:*

Four different radioactive tracers were used to explore the binding characteristics of the charcoal used in the assay: two tritiated forms of anandamide (labeled either on the ethanolamine moiety; anandamide [1-³H-ethanolamine], or on the arachidonic acid moiety; arachidonic acid [5,6,8,9,11,12,14,15-³H (N)]), as well 10 as tritiated arachidonic acid, and ¹⁴C-labeled ethanolamine. Specific amounts of these tracers were incubated with membrane preparations, added to the pre-washed charcoal and recovered by centrifugation, as described in the methods. The recovered radioactivity was counted and expressed as percentage of the amount added. As shown in Fig. 3, when no membranes were present, *i.e.*, there was no FAAH-mediated 15 conversion of anandamide to arachidonic acid plus ethanolamine, neither of the two labeled forms of anandamide could be detected in the flow-through, indicating that the tracers were bound to the charcoal. Tritiated arachidonic acid was also absorbed onto the charcoal and could not be detected in the flowthrough. Of the four tracers used, only the ¹⁴C-ethanolamine could be recovered.

20 It is known that HeLa cells, a human carcinoma cell line, do not express FAAH (Ueda *et al.* (2000) *Chem.Phys.Lipids.* 108:107-121). Therefore, this cell line was used as a negative control, and to investigate the possible contribution of non-FAAH enzymes to the hydrolysis of anandamide. There was essentially no recovery of radioactivity after incubation of ³H-anandamide with HeLa cell membranes, 25 confirming the absence of FAAH (Fig. 3).

When the tracers were incubated with membranes prepared from mouse liver or T84 cells, good recovery of radioactivity was found for the anandamide labeled on the N-terminus of the amide (^3H -ethanolamine), but not for the anandamide carrying the tritium label on the hydrocarbon chain of the fatty acid (^3H -AA). All experiments 5 consistently showed that anandamide and arachidonic acid, in contrast to ethanolamine, were absorbed onto the charcoal column. Therefore, when radiolabeled anandamide is incubated with a cell lysate containing FAAH the radioactivity recovered in the flow-through must be attributed to the radiolabeled ethanolamine. This experiment indicates that it is possible to separate anandamide and 10 ethanolamine using charcoal. Other products, such as SAX and C18 resin were also tested, but were less effective (not shown).

Characterization of the FAAH assay:

FAAH activity is found in a large variety of cells. In rodents, the liver, followed by the brain, seems to have the highest expression of FAAH, whereas in 15 humans, the expression is highest in the pancreas and brain, but lower in the liver (Ueda *et al.* (2000) *Chem.Phys.Lipids.* 108:107-121). The expression of human FAAH mRNA in T84 cells was found by expression profiling using DNA microarrays (not shown) and confirmed by subsequent experiments.

The signal output of the assay was determined to be linear in the range of 20 0.42-3.5 $\mu\text{g}/\text{well}$ T84 membrane. Since an embodiment of the invention is a HTS-compatible assay, it was verified that the reaction was linear over more than 1 hour at the amount of protein used. As shown in Figure 4 A, the rate of the reaction at room temperature was linear over a period of 90 minutes when 3.5 $\mu\text{g}/\text{well}$ protein was used. This experiment was performed both at room temperature and at 37°C, with the 25 enzyme being slightly more active at the higher temperature, as expected. For the

performance of HTS assays, an incubation period of 1 hour at room temperature and a protein amount of 3.5 µg/ well was chosen based on these results.

Kinetic analysis of FAAH activity:

Kinetic analyses of the hydrolysis of anandamide by FAAH in T84 human colorectal carcinoma cells demonstrated a K_m of $1.1 \pm 0.17 \mu\text{M}$. (Fig. 4 B). This is close to the value that has been reported for human brain ($2 \mu\text{M}$, see Maccarrone *et al.* (Maccarrone *et al.* (1999) *Anal. Biochem.* 267:314-318)). Overall, the reported K_m values in the literature for FAAH reactions range widely, from 0.8 to 80 μM , depending on the tissue, species and method used (Fowler *et al.* (2001) *Biochem. Pharmacol.* 62:517-526). For instance, Desarnaud *et al.* (Desarnaud *et al.* (1995) *J. Biol. Chem.* 270, 6030-6035) found a K_m of $12.7 \mu\text{M}$ using rat brain microsomes. In the N18 mouse neuroblastoma cell line, the K_m was determined to be $9.0 \mu\text{M}$ (Maurelli *et al.* (1995) *FEBS Lett.* 377:82-86). Apart from species differences, the variability in these values has been ascribed to the observation that both the substrate and product of this enzyme can form micelles, which may affect the enzyme activity (Fowler *et al.* (2001) *Biochem. Pharmacol.* 62:517-526).

Validation of the FAAH assay using reference compounds:

Several of the FAAH inhibitors that have been described in the literature were tested in the assay to validate its ability to identify inhibitors. Of the inhibitors that are commercially available, methyl arachidonyl fluorophosphate (MAFP), which is also an inhibitor of cytosolic phospholipase A₂, is the most potent, with reported IC₅₀ values of 1-3 nM (Ueda *et al.* (2000) *Chem. Phys. Lipids* 108, 107-121; Deutsch *et al.* (1997) *Biochem. Pharmacol.* 53, 255-260). Its potency as an inhibitor of FAAH was confirmed with the determination of an IC₅₀ value of 0.8 nM.

Oleyl trifluoromethyl ketone, a transition-state inhibitor, has also been reported to be a potent inhibitor of FAAH, with an IC₅₀ of 73.3 nM in the studies here presented, it was in the same range as the IC₅₀ values of 28 - 41 nM found by Tiger *et al.* (2000; *Biochem. Pharmacol.* 59, 647-653).

5 Phenylmethanesulfonyl fluoride, an inhibitor of serine proteases, was shown to be an inhibitor of FAAH, although with a low potency. Its pIC₅₀ for the inhibition of rat brain FAAH in another group was between 5.92 and 4.16, depending on the pH (Holt *et al.* (2001) *Br. J. Pharmacol.* 133, 513-520). At a concentration of 100 µM, it abolished anandamide hydrolysis in N18 mouse neuroblastoma cells (Maurelli *et al.* 10 (1995) *FEBS Lett.* 377, 82-86). It was used at a concentration of 1.5 mM by Deutsch *et al.* (1993; *Biochem. Pharmacol.* 46, 791-796) to block FAAH activity in neuroblastoma and glial cells. At 25 µM, it inhibited the hydrolysis of rat brain microsomal anandamide by 48 % (Desarnaud *et al.* (1995) *J. Biol. Chem.*, 270, 6030-6035). The IC₅₀ value (16 µM) obtained in this work thus corresponds well to the 15 numbers reported in the literature.

Finally, product inhibition was tested by using the FAAH products oleic acid and arachidonic acid. Maurelli *et al.* (1995; *FEBS Lett.* 377, 82-86) found that 100 µM anandamide abolished the activity of FAAH. In this work, these compounds inhibited FAAH activity with IC₅₀ values in the low micromolar range (Table 1).

20 These results confirm that the assay provides a robust method for the evaluation of FAAH activity. The assay was successfully validated using reference inhibitors. As the assay may be performed simultaneously in multiple reactions, such as in a 96 well plate, for example, the assay is adaptable for high-throughput screening of compound collections as well as natural product or combinatorial 25 libraries.

Table 1. Activity of known FAAH inhibitors in T84 membranes

COMPOUND	IC ₅₀ (nM)	Literature (ref)
Methyl arachidonyl fluorophosphate	0.8 ± 0.7	2.5 ⁽¹⁾ 1-3 ⁽²⁾
Oleyl trifluoromethyl ketone	73.3 ± 19.8	39 ⁽³⁾ 24-41 ⁽⁴⁾
Phenylmethylsulfonyl fluoride	15978 ± 8863	1200-69000 ⁽⁵⁾
Arachidonic acid	931.4 ± 255.4	-
Oleic acid	1936 ± 401	-

The average ± S.E. of values obtained in 2-5 experiments , each done in triplicate, is given. The numbers in the column on the right refer to literature data. References : (1) : Deutsch *et al.* Biochem. Pharmacol. 1997, 53: 255-260. (2) : Ueda *et al.* Chem. Phys. Lipids 2000, 108 : 107-121. (3) Fowler *et al.* Br. J. Pharmacol. 2000, 131: 498-504. (4) Tiger *et al.* Biochem. Pharmacol. 2000, 59:647-653. (5) Holt *et al.* Br. J. Pharmacol. 2001, 133: 513-520.

The foregoing description, examples and accompanying figures generally describe the invention. The description is for purposes of providing illustrations; the present invention is not to be limited by the specific embodiments described herein. One of skill in the art will appreciate that various modifications of the invention may be made in addition to those described herein. Such modifications are intended to fall within the scope of the appended claims.

Pig FAAH Nucleic Acid Sequence (SEQ ID NO:1)

cggtcctcg gg tggagatca tggcagga agaactgtgg gtcgcgttcc
ccggccctc cgggttgcc ctggctgct gcttgggtgc agcggcccttgc
gccctgcgtt gttccagtcg ccggatggcg cggggcgcgg cggcccggc
gacacagg cagcaagcgg ccctggagac catggacaag gcccgcgc
gcttccggct ccagaacccc gatctggact cggagatgct gtcggccctg
ccactgcctc agctggata gaaggtacga agtggggagc tgcgtccaga
ggctgtgctc ttttccattc tgcaaaaaggc ctgggaagtgc aacagagg
ccaactgcgt gaccacctac ctggcagact gtgaggctca gtcgtgccag
gcccggc agggcctgt ctacgggtgc cccgtcagcc tcaaggagtg
cttcagctgc aaggccatg actccacgt gggcttgagc cggaaaccagg
ggacaccaggc agaatgtgac tgcgtgggtgg tgcaggtgct gaaactgc
ggtgctgtgc ttccgtgca caccaacgtc ccccaagtcca tggtcagcta
tgactgcagt aacccctct ttggccagac caccaaccca tggatgtcgt
ccaagagccc gggcggtcc tcgggaggtg agggggccct cattgtcgt
ggaggctccc cactgggctt aggcaccgc acatggggca gcatccgctt
tccctccgcc ttctgtggca tctgccccat caaaccacg gggaaaccgca
tcagcaagag tggctctgaag ggctctgtct atggacagg tgcgtgc
ctctcagtgg gccccatggc gcgggacgtg gagagcctgg ccctgtgc
gcgtgcgtc ctgtgcgaag acatgttccg cctggacccc acggtgcc
ccctgcctt caacggagg gtctacgcaa gctctcgcc cctgcgtgt
gggtattatg agaccgacaa ctacaccatg cccacgggg ccatgagg
ggccctgctg gagaccaagc ggagccttga ggctgcggc cacacgctga
ttcccttcctt gcccggcaac atacccacg ctctggaggc cctgtcaac
ggcggctct tcagtgtatgg tggaaagagg ttgctacaga acttcgaagg
cgattacgtg gactcctgct tagggacact gatctaatt ctgaggctc
ccaaatggct taaaggactg ctggcttca tgctgaggcc tctgctccca
aggttggcag gctttcttag cagcctgagg cctcggtcgg ctggaaagct
ctggaaactg cagcacgaga ttgagatgta cctgtactcc gtgattgccc
agtggcgagc gctggacccg gatgtgggtgc taaccccat gctgagcc
gccctagact tgaatgcccc aggaaggcc acaggggccg tcagctac
gctgctctac aactgcctgg acttccccgc ggggggtggc cctgtcacca
cggtgactgc cgaggacgag gcccagatgg agcattacaa gggctactt
ggggacattt gggacaagg ggtcagaag gccatgaaga ggagcgtgg
gctgcctgtg gccgtcgt gttgggtct gcccggcag gaggagctgt
gtttgcgggtt catgcggag gtggagcgtc tgatggctcc tggcggc
ccctcctgac cgctgcccgc ccggcccccc aggacctgag acccaactg
tccgcggcca gcgagtcag gacacaactg ccaccgtcga agaaaatgtt
caacccctcagg cagaggcttc ccgtctctc cccctcgccc ctgccaga
cccagaacca ctgagtcgtt accttgcgtt tccctggc cctgtctgc
cctgaccccg ccaatgtggc agcttagtggg tatgacatgg caaaggccc
ccaaccgtca aaaaccgtt cctggcttcc atacttctg gcaatgtc
ttagggcgtt ggggggttgg gacgtgttgc tctggaaaccc gactcc
atgtccgtct cgtgctgcag aagcttctt ggtcctgc actcacggc
agacaccggc ttctccgtt gggcccttgc gcccaggact tcacccccc
gccccccagcc taagccctac tttgcggaggc attgtttctt ctcctgc
ctgctgaggc tgcccttctt gtcctctac cattaaatcc tttggaggccc

Pig FAAH Amino Acid Sequence (SEQ ID NO:2)

MVQEELWAAF SGPSGVALAC CLVAAALALR WSSRRMARGA AARARQRQQA
 ALETMDKAAQ RFRLQNPDL D SEMLLALPLP QLVQKVRSGE LSPEAVLFSY
 LQKAWEVNRG TNCVTTYLAD CEAQLCQAPG QGLLYGVPVS LKECFSCKGH
 DSTLGLSRNQ GTPAECDCVV VQVLKLQGAV PFVHTNVPQS MFSYDCSNPL
 FGQTTNPWMS SKSPGGSSGG EGALIAAGGS PLGLGTDIGG SIRFPSAFCG
 ICGIKPTGNR ISKSGLKGSV YGQVAVQLSV GPMARDVESL ALCLRALLECE
 DMFRLDPTVP PLPFNEEVYA SSRPLRVGYY ETDNYTMPTP AMRRALLETK
 RSLEAAAGHTL IPFLPANIPH ALEALSTGGL FSDGGKRLLQ NFEQDYVDSC
 LGDLISILRL PKWLKGLLAF MLRPLLPRLA GFLSSLRPRS AGKLWELQHE
 IEMYRHNSVIA QWRALDLDVV LTPMLSPALD LNAPGKATGA VSYTLLYNCL
 DFPAGVVVPVT TVTAEDEAQ M EHYKGYFGDI WDKVVQKAMK RSVGLPVAVQ
 CVALPWQEEL CLR FMREVER LMAPGRQPS

Mouse FAAH Nucleic Acid Sequence (SEQ ID NO:3)

atggtgctga gcgaagtgtg gaccgcgctg tctggactct ccggggtttgc
 cctagcctgc agcttgctgt cgccggcggt ggtcctgcga tggaccaggaa
 gccagaccgc ccggggcgcg gtgaccagggg cgccggcagaa gcagcgagcc
 ggcctggaga ccatggacaa ggcgggtgcag cgcttcggc tgcagaatcc
 tgacctggat tcagaggcct tgctggctct gcccctgctc caactggta
 agaagttaca gagtggggaa ctgtccccag aagctgtgct ctttacctac
 ctggggaaagg cctgggaagt gaacaaagg accaactgtg tgacctccta
 tctgactgac tgtgagactc agctgtccca ggccccacgg cagggcctgc
 tctatggcgt ccccgtgagc ctcagaagaaat gcttcagcta caagggccat
 gcttcacac tgggcttaag tttgaacgag ggtgtgacat cggagagtga
 ctgtgtggtg gtgcaggtac tgaagctgca gggagctgtg cccttgc
 acaccaacgt ccccccagtcc atgtaagct atgactgcg taacccccc
 tttggccaga ccatgaaccc gtgaaagccc tccaagagtc caggaggc
 ctcagggggt gagggggctc tcattggatc tggaggctcc cctctgggtt
 taggcactga catcgccggc agcatccggt tcccttctgc cttctgtgc
 atctgtggcc tcaagcctac tggaaaccgc ctcagcaaga gtggcctgaa
 gagctgtgtt tatggacaga cagcagtgca gctttctgtt ggccccatgg
 cacggatgt ggatagcctg gcattgtgca taaaagccct actttgtgag
 gatttttcc gcttggactc caccatcccc cccttgcct tcagggagga
 gatctacaga agttctcgac cccttcgtgt gggatactat gaaactgaca
 actacaccat gcccactcca gccatgagga gggctgtgat ggagaccaag
 cagagtctcg aggctgctgg ccacacgctg gtcccccct taccaaaca
 cataccttat gcccctggagg tcctgtcggc aggtgggctg ttcaagtatg
 gtggctgctc ttttctccaa aacttcaaag ggcactttgt ggatccctgc
 ttgggggacc tggcttagt gctgaagctg cccaggtgg taaaaaaact
 gctgagcttc ctgctgaagc ctctgtttcc tcggctggca gcctttctca
 acagtagtg tcctcggtca gcccggaaact tggggact gca gcatgag
 attgagatgt atcgccagtc cgtcattgcc cagtggaaagg caatgaacct
 ggacgtggtg ctaacccca tgctgggtcc tgctctggat ttgaacacac
 cgggcagagc cacaggggct atca gactaca ctgttctcta taactgc
 gacttccctg cgggggtggt gcctgtcacc actgtgaccg ctgaggacga
 tgcccagatg gaacactaca aaggctactt tggggatatg tgggacaaca
 ttctgaagaa gggcatgaaa aagggtatag gcctgcctgt ggctgtgc
 tgcgtggctc tgcctggca ggaagagctg tgcgtgcgg tcatgcggga

ggtggaacgg ctgatgaccc ctgaaaagcg gccatcttga

Mouse FAAH Amino Acid Sequence (SEQ ID NO:4)

MVLSEWWTAL SGLSGVCLAC SLLSAAVVLR WTRSQTARGA VTRRARQKQRA
 GLETMDKAVQ RFRLQNPDLQ SEALLALPLLI QLVQKLQSGE LSPEAVLFTY
 LGKAWEVNKG TNCVTSYLTQ CETQLSQAPR QGLLYGVPVS LKECFSYKGH
 ASTLGLSLNE GVTSESDCCVQ VQVLKLQGAV PFVHTNVPQS MLSYDCSNPL
 FGQTMNPWKPSKSPGGSSGG EGALIGSGGS PLGLGTDIGG SIRFPSAFCG
 ICGLKPTGNR LSKSGLKSCV YGQTAVQLSV GPMARDVDSL ALCMKALLCE
 DLFRLDSTIP PLPFREEIYR SSRPLRVGYY ETDNYTMPTP AMRRAVMETK
 QSLEAAAGTL VPFLPNNIPIY ALEVLSAGGL FSDGGCSFLQ NFKGDFVDPC
 LGDLVLVLKL PRWFKKLLSF LLKPLFPRLA AFLNSMCPRS AEKLWELQHE
 IEMYRQSVIA QWKAMNLDDVV LTPMLGPALD LNTPGRATGA ISYTVLYNCL
 DFPAGVVPVTTVTAEDDAQM EHYKGYFGDM WDNIILKKGMK KGIGLPVAVQ
 CVALPWQEEL CLRFMREVER LMTPEKRPS

Rat FAAH Nucleic Acid Sequence (SEQ ID NO:5)

ggtttgtgcg agccgagttc ttcgggtgg cggtcggctg caggagatca
 tggtgcttag cgaagtgtgg accacgctgt ctggggctc cgggggttgc
 cttagcctgca gcttgttgc ggcggcgggtg gtcctgcgtt ggaccgggccc
 ccagaaggcc cggggcgcgg cgaccaggcc gcggcagaag cagcggcc
 gcctggagac catggacaag gcggtgcagc gttccggct gcagaatcct
 gacctggact cggaggccctt gctgaccctg cccctactcc aactggtaca
 gaagttacag agtggagagc tggcccccaga ggctgttgc ttacttacc
 tggaaaggc ctggaaagtg aacaaaggga ccaactgcgt gaccccttat
 ctgaccgact gtgagactca gctgtcccag gccccacggc agggcctgct
 ctatgggtgc cctgtgagcc tcaaggaatg cttcagctac aagggccacg
 actccacact gggcttgagc ctgaatgagg gcatggccatc ggaatctgac
 tgtgtggtgg tgcaagtgtt gaagctgcag ggagctgtgc cctttgtgca
 taccaatgtc ccccagtcca tggtaagctt tgactgcagt aaccctct
 ttggccagac catgaacccca tggaaagtctt ccaagagccc aggaggttcc
 tcaggggggtg agggggctctt cattggatct ggaggttccc ctctgggaaa
 aggcactgac attggcgca gcatccgggtt cccttctgccc ttctgcggca
 tctgtggctt caagcctact ggcaaccggcc tcagcaagag tggcctgaag
 ggctgtgtct atggacagac ggcagtgcag ctttcttgc gccccatgac
 ccggatgtg gagagcctgg cgctatgcctt gaaagctcta ctgtgtgagc
 acttggtcac cttggaccctt accgtgcctc ctttgcctt cagagaggag
 gtctatagaa gttcttagacc cctgcgtgtg ggttactatg agactgacaa
 ctataccatg cccagcccaag ctatgaggag ggctctgata gagaccaagc
 agagacttga ggctgtggc cacacgctga ttcccttctt acccaacaac
 ataccctacg ccctggaggt cctgtctgca ggcggcctgt tcagtgacgg
 tggcccgagt tttctccaaa acttcaaagg tgactttgtg gatccctgt
 tggagacactt gatcttaatt ctgaggctgc ccagctgggtt taaaagactg
 ctgagcctcc tgctgaagcc tctgtttccctt cggctggcag ctttctcaa
 cagtagcgt cctcggtcag ctgaaaagct gtggaaactg cagcatgaga
 ttgagatgta tcgcccgtct gtgattgccc agtggaaagc gatgaacttg
 gatgtgtgc tgaccccat gttggccctt gctctggatt tgaacacacc
 gggcagagcc acaggggcta tcagctacac cgttctctac aactgcctgg
 acttccctgc ggggtggc cctgtcacca ctgtgaccgc cgaggacat

gcccagatgg aactctacaa aggctacttt gggatatct gggacatcat
 cctgaagaag gccatgaaaa atagtgtcg tctgcctgtg gctgtgcagt
 gcgtggctct gccctggcag gaagagctgt gtctgagggtt catgcggag
 gtgaaacagc ttagtgcaccc tc当地aaagcag cc当地ctgtgag ggtcggtcat
 cc当地cagctc tggaggacct aaggcccatt cgctgtgcac tt当地agcccc
 tgtattcagg agccaccacc cacgaggaa cgcccagcac agggaaagagg
 tgtctacctg cc当地ccctg gactctgc当地 gccaacaacca agtctggacc
 tt当地ccctg tt当地ggctta ct当地ccatcc tgattccctg ct当地ttatgg
 cagccagcag gaatgacgtg ggccaaggat caccaacatt caaaaacaat
 gc当地ttatct attttctgg tatctccatt agggccctgg gaaccagagt
 gctggaaagg ctgtccagac cctccagagc tggctgtac cacatcactc
 tc当地gtccca aaggccctct agtctgtca cccacaagat agacacaggg
 acatgtcctt ggcacttgac tc当地gtcctt ct当地tttat tcaaggattgac
 cccagccctg atggaccctg cccctgcact tc当地tc当地ca gtccacccct
 ctgcccacac gccc当地ta tggctcctct atttggttg gagacaagg
 tt当地tc当地t agccctggct gtccaggacc tcaactctgtt gatgaggctg
 gcttcaact cacaaggctg cctgc当地ggg tgctggatt aaaggcgtat
 gccc当地cacaagaaaaaa aa

Rat FAAH Amino Acid Sequence (SEQ ID NO:6)

MVLSEVWTTL SGVSGVCLAC SLLSAAVVLR WTGRQKARGA ATRAROKQRA
 SLETMDKAVQ RFRLQNPDL D SEALLTLPLL QLVQKLQSGE LSPEAVFFTY
 LGKAWEVNKG TNCVTSY LTD CETQLSQAPR QGLLYGVPVS LKECFSYKGH
 DSTLGLSLNE GMPSESDCVV VQVILKLQGAV PFVHTNVPQS MLSFDCSNPL
 FGQTMMNPWKS SKSPGGSSGG EGALIGSGGS PLGLGTDIGG SIRFPSAFCG
 ICGLKPTGNR LSKSGLKGCV YGQTAQVQLSL GPMARDVESL ALCLKALLCE
 HLFTLDPTVP PLPFREEVYR SSRPLRVGYY ETDNYTMPSP AMRRALIETK
 QRLEAAAGHTL IPFLPNNIPIY ALEVLSAGGL FSDGGRSFLQ NFKGDFVDP
 LGDLILILRL PSWFKRLLSL LLKPLFPRLA AFLNSMRPRS AEKLWKLQHE
 IEMYRQSVIA QWKAMNLSDL LTPMLGPALD LNTPGRATGA ISYTVLYNCL
 DFPAGVVVPVT TVTAEDDAQM ELYKGYFGDI WDIILKKAMK NSVGLPVAVQ
 CVALPWQEEL CLRHMREVEQ LMTPQKQPS

Human FAAH Nucleic Acid Sequence (SEQ ID NO:7)

tgccggccgg taggcagcag caggctgaag ggatcatggc gca gtc acg
 ctgtggccgg cgctgcctgg cgc当地ccggg gtc当地ccctgg cctgctgctt
 cgtggccggc gccc当地ggcc tgc当地gtggc cgggcccgg acggccgg
 gccc当地gtgtt cgggcccggc cagaaggcagc gagcggccct ggagaacatg
 gacaggccgg cgc当地gc当地t cc当地ctccag aaccaggacc tggactc
 ggc当地ctgcta gccc当地ccccc tgc当地ctcagct ggtgc当地aaag
 tt当地acacagta gagagctggc cc当地tggaggcc gtgc当地ttca
 cctatgtggg aaaggccctgg gaagtaaca aagggacaa ctgtgtgacc
 tc当地tatctgg ctgactgtga gactc
 actg tctcaggccc caaggcagg
 cctgctctat ggc当地ccctg tgagc
 ctcaa ggagtgctt acctacaagg gcaaggactc
 cactg
 tt当地gaggctga atgaagggg
 gccc当地ggag
 tgc当地acagcg tagtgg
 tgc当地tgaag
 ctgcagggt
 cc当地tgc当地t
 cgtgc当地acacc
 aatgttccac
 agtccatgtt
 cagctatgac
 tgc当地tacc
 cc当地tcttgg
 cc当地accgtg
 aacc
 catgga
 agtcc
 ctccaa
 aaggccagg
 ggctc
 ctccag
 ggggt
 gaaagg
 ggcc
 ctc当地t
 ggg
 tctgg
 gag
 ggc当地ttaggc
 actgatata
 cg

gaggcagcat ccgcttcccc tcctccttgc gcccacatcg cggcctcaag
 cccacaggga accgcctcag caagagtggc ctgaagggt gtgtctatgg
 acaggaggca gtgcgtctct ccgtggccc catggcccg gacgtggaga
 gcctggact gtgcctgcga gccctgctgt gcgaggacat gttccgcttg
 gaccctactg tgcctccctt gcccttcaga gaagaggtct acaccagctc
 tcagcccctg cgtgtgggt actatgagac tgacaactat accatgccct
 ccccggccat gaggcgggccc gtgctggaga ccaaacagag ccttgaggct
 gcggggcaca cgctggttcc ttcttgcca agcaacatac cccatgctct
 ggagaccctg tcaacaggtg ggctttcag tgatggggc cacaccccttcc
 tacagaactt caaagggtgat ttcgtggacc cctgcctggg ggacctggc
 tcaattctga agcttccca atggctaaa ggactgctgg ccttcctgg
 gaagcctctg ctgccaaggc tgtagcttt cctcagcaac atgaagtctc
 gttcgtgtgg aaaactctgg gaactgcagc acgagatcga ggtgtaccgc
 aaaaccgtga ttgcccagtg gagggcgctg gacctggatg tggtgctgac
 ccccatgctg gcccctgctc tggacttcaa tgcccccaggc agggccacag
 gggccgtcag ctacactatg ctgtacaact gcctggactt ccctgcaggg
 gtgggcctg tcaccacgg gactgctgag gacgaggccc agatggaaaca
 ttacaggggc tactttgggg atatctggga caagatgctg cagaagggca
 tgaagaagag tggggggctg ccggtgcccg tgcatgtgt ggctctgccc
 tggcaagaag agttgtgtct gcggttcatg cgggaggtgg agcgactgat
 gaccctgaa aagcagtcat cctgatggct ctggctccag aggacctgag
 actcacactc tctgcagccc agcctagtca gggcacagct gccctgctgc
 cacagaagg aaatgtcctg catggggcag aggctccgt gtccctctccc
 ccaacccct gcaagaagcg ccgactccct gagtctggac ctccatccct
 gctctgtcc cctctcttcg tcctgatccc tccaccccca tgtggcagcc
 catgggtatg acataggcca aggcccaact aacagtcaag aaacaaaaaaa
 aaaaaaaaaaaa aaa

Human FAAH Amino Acid Sequence (SEQ ID NO:8)

MVQYELWAAL PGASGVALAC CFVAAAVALR WSGRRRTARGA VVRARQKQRA
 GLENMDRAAQ RFRLQNPDLD SEALLALPLP QLVQKLHSRE LAPEAVLFTY
 VGKAWEVNKG TNCVTSYLAQ CETQLSQAPR QGLLYGVPVS LKECFTYKGQ
 DSTLGLSLNE GPVAECDSVV VHVLKLQGAV PFVHTNVPQS MFSYDCSNPL
 FGQTVNPWKS SKSPGGSSGG EGALIGSGGS PLGLGTDIGG SIRFPSSFCG
 ICGLKPTGNR LSKSGLKGCV YGQEAVRLSV GPMARDVESL ALCLRALLCE
 DMFRLDPTVP PLPFREEVYT SSQPLRVGYY ETDNYTMAPSP AMRRAVLETK
 QSLEAAAGHTL VPFLPSNIPH ALETLSTGGL FSDGGHTFLQ NFKGDFVDP
 LGDLVSLKL PQWLKGLLAF LVKPLLPRLS AFLSNMKSRS AGKLWELQHE
 IEVYRKTVIA QWRALLDLVV LTPMLAPALD LNAPGRATGA VSYTMLYNCL
 DFPAGVVPVT TVTAEDEAQM EHYRGYFGDI WDKMLQKGMK KSVGLPVAVQ
 CVALPWQEEL CLRFMREVER LMTPEKQSS

What is claimed is:

1. A method of assaying the activity of a fatty acid amide hydrolase comprising the steps of:
 - combining a sample suspected of containing a fatty acid amide hydrolase, with a labeled substrate of the fatty acid amide hydrolase, to form a reaction mixture;
 - incubating the reaction mixture under conditions sufficient to allow the fatty acid amide hydrolase to hydrolyze the labeled substrate, thereby forming at least one labeled hydrolysis product;
 - contacting the incubated reaction mixture with a selective binding material; wherein the selective binding material binds either the labeled substrate or a labeled hydrolysis product, but not both, thereby forming a bound labeled complex;
 - separating the bound labeled complex from the incubated reaction mixture;and
 - determining an amount of labeled substrate hydrolyzed, or labeled hydrolysis product formed, thereby indicating the fatty acid amide hydrolase activity of the sample.
2. The method of claim 1 wherein the sample comprises biological membranes, lipid bilayers, or micelles.
3. The method of claim 1 wherein the substrate is an endocannabinoid, a fatty acid ethanolamide, a fatty acid primary amide, an endocannabinoid analog, a fatty acid ethanolamide analog, or a fatty acid primary amide analog.
4. The method of claim 1 wherein the substrate is anandamide.

5. The method of claim 1 wherein the substrate is oleamide.
6. The method of claim 1 wherein the substrate is 2-arachidonoylglycerol.
7. The method of claim 1 wherein the substrate is labeled with a radioisotope.
8. The method of claim 7 wherein the radioisotope is ^3H or ^{14}C .
9. The method of claim 1 wherein the substrate is labeled with a fluorescent label.
10. The method of claim 1 wherein the selective binding material comprises carbon.
11. The method of claim 10 wherein the selective binding material is activated charcoal.
12. The method of claim 11 wherein the activated charcoal comprises a filter.
13. The method of claim 1 wherein the selective binding material binds the labeled substrate but not the labeled product.
14. The method of claim 1 wherein the separating step comprises filtration, gravity settling or centrifugation.

15. The method of claim 1 wherein the determining step is performed via liquid scintillation counting or by measurement of fluorescence energy.

16. The method of claim 1 conducted in a multiwell plate.

17. The method of claim 1 comprising at least a portion of a high throughput screening program.

18. The method of claim 1 wherein the method is conducted in conjunction with a drug discovery effort.

19. A method of identifying a compound that modulates the activity of a fatty acid amide hydrolase comprising the steps of:

comparing the activity of a fatty acid amide hydrolase as assayed by the method of claim 1, in the presence and in the absence of a test compound added to the reaction mixture;

wherein a change in the activity of the fatty acid amide hydrolase indicates that the test compound modulates the activity of the fatty acid amide hydrolase.

20. The method of claim 19 wherein the test compound is selected from a library of compounds.

21. The method of claim 19 wherein the test compound inhibits the activity of the fatty acid amide hydrolase activity.

22. The method of claim 21 wherein said fatty acid amide hydrolase activity is inhibited at least about 5%.

23. The method of claim 21 wherein said fatty acid amide hydrolase activity is inhibited at least about 20%.

24. The method of claim 21 wherein said fatty acid amide hydrolase activity is inhibited at least about 50%.

25. The method of claim 21 wherein said fatty acid amide hydrolase activity is inhibited at least about 80%.

26. The method of claim 21 wherein said fatty acid amide hydrolase activity is inhibited at least about 95% or more.

27. The method of claim 21 wherein said test compound increases said fatty acid amide hydrolase activity.

28. The method of claim 27 wherein said fatty acid amide hydrolase activity is increased at least about 5%.

29. The method of claim 27 wherein said fatty acid amide hydrolase activity is increased at least about 30%.

30. The method of claim 27 wherein said fatty acid amide hydrolase activity is increased at least about 50%.
31. The method of claim 27 wherein said fatty acid amide hydrolase activity is increased at least about 70%.
32. The method of claim 27 wherein said fatty acid amide hydrolase activity is increased at least about 100%.
33. The method of claim 27 wherein said fatty acid amide hydrolase activity is increased between about two-fold to about ten-fold.
34. The method of claim 19, which comprises the use of a multi-well plate.
35. The method of claim 19 conducted in a multiwell plate.
36. The method of claim 19 comprising at least a portion of a high throughput screening.
37. The method of claim 19 wherein the method is conducted in conjunction with a drug discovery effort.
38. The method of claim 1 wherein said fatty acid amide hydrolase is a mammalian fatty acid amide hydrolase.

39. The method of claim 38 wherein said fatty acid amide hydrolase is a porcine fatty acid amide hydrolase.

40. The method of claim 38 wherein said fatty acid amide hydrolase is a rodent fatty acid amide hydrolase.

41. The method of claim 38 wherein said fatty acid amide hydrolase is a murine fatty acid amide hydrolase.

42. The method of claim 41 wherein said fatty acid amide hydrolase is a rat fatty acid amide hydrolase.

43. The method of claim 41 wherein said fatty acid amide hydrolase is a mouse fatty acid amide hydrolase.

44. The method of claim 38 wherein said fatty acid amide hydrolase is a human fatty acid amide hydrolase.

45. A method for determining altered fatty acid amide hydrolase activity in a patient comprising:

obtaining a sample containing cells from the patient;
lysing the cells to form a cell lysate;
combining the cell lysate with a labeled substrate of fatty acid amide hydrolase, to form a reaction mixture;

incubating the reaction mixture under conditions sufficient to allow a fatty acid amide hydrolase present in the cell lysate to hydrolyze the labeled substrate, thereby forming at least one labeled hydrolysis product;

contacting the incubated reaction mixture with a selective binding material; wherein the selective binding material binds either the labeled substrate or a labeled hydrolysis product, but not both, thereby forming a bound labeled complex;

separating the bound labeled complex from the incubated reaction mixture;

determining an amount of labeled substrate hydrolyzed, or labeled hydrolysis product formed, thereby indicating the fatty acid amide hydrolase activity of the sample; and

comparing the activity of the sample from the patient with the activity of a to a predetermined value for activity, to determine if the patient has altered fatty acid amide hydrolase activity relative to the predetermined value for activity.

46. The method of claim 45 wherein said patient is female.

47. The method of claim 46 wherein the female is pregnant or is seeking fertility treatment.

48. The method of claim 45 wherein the sample comprises blood, tissue or body fluid.

49. The method of claim 46 wherein the sample comprises lymphocytes.


50. The method of claim 45 wherein the cells are homogenized.

51. The method of claim 45 wherein the fatty acid amide hydrolase activity present in the cell lysate is partially or substantially purified from the sample.


52. The method of claim 45 wherein the predetermined determined value is from a control assay, a prior or subsequent sample from the patient, a sample from a normal individual, a sample from another patient, a standard FAAH, or a predetermined value.

1/4


Step 1 : incubate ³H-anandamide
with FAAH-containing membranes



FAAH



Step 3 : centrifuge



Step 4 : add scintillant to flow-through
and count




FIG 1

2/4





FIG 2

SUV

3/4

**FIG 3**

4/4




FIG 4A




FIG 4B

10/531777

JC13 Rec'd PCT/PTO 19 APR 2009
PCT/US2003/035354

WO 2004/037371

SEQUENCE LISTING

<110> Barbier, Ann Johanna
Wilson, Sandy J,
Mazur, Curt

<120> Assay for Determining the Activity of Fatty Acid Amide Hydrolase

<130> PRI0002

<160> 8

<170> PatentIn version 3.1

<210> 1
<211> 2300
<212> DNA
<213> Sus scrofa

<400> 1
cgggtcctcg tgggagatca tggtgccagg agaactgtgg gctgcgttct ccggccccctc 60
cggggttgcc ctggcctgct gcttggtggc agcggccttgc cccctgcgtt ggtccagtcg 120
ccggatggcg cggggcgcgg cgccccggc gcgcacagagg cagcaagcgg ccctggagac 180
catggacaag gcggcgcage gcttccggct ccagaacccc gatctggact cggagatgct 240
gctggccctg ccactgcctc agctggtaca gaaggtacga agtggggagc tgcgtccaga 300
ggctgtgctc tttcctacc tgcaaaaaggc ctgggaagtgc aacagagggc ccaactgcgt 360
gaccacccatc ctggcagact gtgaggctca gctgtgccag gcgcggggc agggcctgct 420
ctacggtgtc cccgtcagcc tcaaggagtgc ttctcagtc aaggccatg actccacgct 480
gggcttgagc cgaaaccagg ggacaccaggc agaatgtgac tgcgtggtgg tgcaggtgct 540
gaaactgcag ggtgtgtgc ctggcgtgca caccaacgtc ccccaagtcca tgcgtccata 600
tgactgcagt aacccctct ttggccagac cacgaaccca tggatgtcgta ccaagagccc 660
ggcggtcc tcgggagggtg agggggccctt cattgtgtgc ggaggctccc cactggctt 720
aggcaccgac atcggggcga gcatccgctt tccctccggc ttctgtggca tctgcggcat 780
caaaccacg ggaaaccgca tcagcaagag tggctgtgaag ggctctgtct atggacaggt 840
agcagtgcag ctctcagtgcc gccccatggc gcggjacgtg gagagcctgg ccctgtgcct 900
gcgtgcgcgtc ctgtgcgaag acatgttccgc cctggacccc acgggcgcctc ccctgcctt 960
caacgaggag gtctacgca gctctcgcc cctgcgtgtc gggtattatg agaccgacaa 1020
ctacaccatg cccacgcggc ccatgaggcg ggccctgcgtc gagaccaagc ggagccttga 1080
ggctgcgggc cacacgcgtga ttcccttcct gccggccaac atacccacg ctctggaggc 1140
cctgtcaacg ggcgggtctc tcagtgtatgg tggaaagagg ttgctacaga acttcgaagg 1200
cgattacgtg gactcctgct taggggacct gatctcaatt ctgaggctgc ccaaatggct 1260
taaaggactg ctggcttca tgctgaggcc tctgcgtccaa aggtggcag gcttctcag 1320
cagcctgagg cctcggtcgg ctggaaagct ctggaaactg cagcacgaga ttgagatgta 1380
ccgtcactcc gtgattgccc agtggcgagc gctggacctg gatgtggtgc taaccccat 1440
gctgagccct gcccgtact tgaatgcccc aggcaaggcc acagggggccg tcagctacac 1500
gctgtctac aactgcctgg acttccccgc ggggggtggtgc cctgtcacca cgggtactgc 1560

cgaggacgag	gcccagatgg	agcattacaa	ggctacttt	ggggacattt	gggacaagg	1620
ggtcagaag	gccatgaaga	ggagcgtggg	gctgcctgtg	gccgtgcagt	gtgtggctct	1680
gccctggcag	gaggagctgt	gtttcggtt	catgcgggag	gtggagcgcac	tatggctcc	1740
tgggcggcag	ccctcctgac	cgctgcccgc	ccggcccccc	aggacctgag	accactgga	1800
tccgcgccc	gcggagtcag	gacacaactg	ccaccgtgca	agaaaatgtt	caacctcagg	1860
cagaggctc	ccggctctc	cccctgccc	ctgccagaag	cccagaacca	ctgagctgg	1920
accttgctct	tcccgtggc	cctgctctgc	cctgaccccg	ccaatgtggc	agctagtgg	1980
tatgacatgg	caaaggcccc	ccaaacgtca	aaaacgggtt	cctggctcc	atacttctg	2040
gcagtcgtt	ttagggcagt	gggggttgg	gacctgacct	tctggAACCC	gactccagcc	2100
atgtccgtct	cgtgctgcag	aagcttctct	ggtcctcgtc	actcacggc	agacacccggc	2160
ttctccgagt	gggccttgca	gcccaggact	tcacccggcc	gccccagcc	taagccctac	2220
tttgcgagc	attgtcttct	ctcctgccc	ctgctgaggg	tgccctttct	gctcctctac	2280
cataaaaatcc	tttgaggccc					2300

<210> 2
<211> 579
<212> PRT
<213> Sus scrofa

<400> 2

Met	Val	Gln	Glu	Glu	Leu	Trp	Ala	Ala	Phe	Ser	Gly	Pro	Ser	Gly	Val
1					5				10					15	

Ala	Leu	Ala	Cys	Cys	Leu	Val	Ala	Ala	Ala	Leu	Ala	Leu	Arg	Trp	Ser
					20				25				30		

Ser	Arg	Arg	Met	Ala	Arg	Gly	Ala	Ala	Ala	Arg	Ala	Arg	Gln	Arg	Gln
						35			40			45			

Gln	Ala	Ala	Leu	Glu	Thr	Met	Asp	Lys	Ala	Ala	Gln	Arg	Phe	Arg	Leu
						50		55			60				

Gln	Asn	Pro	Asp	Leu	Asp	Ser	Glu	Met	Leu	Leu	Ala	Leu	Pro	Leu	Pro
							65	70	75			80			

Gln	Leu	Val	Gln	Lys	Val	Arg	Ser	Gly	Glu	Leu	Ser	Pro	Glu	Ala	Val
						85		90			95				

Leu	Phe	Ser	Tyr	Leu	Gln	Lys	Ala	Trp	Glu	Val	Asn	Arg	Gly	Thr	Asn
							100	105			110				

Cys	Val	Thr	Thr	Tyr	Leu	Ala	Asp	Cys	Glu	Ala	Gln	Leu	Cys	Gln	Ala
							115	120			125				

Pro	Gly	Gln	Gly	Leu	Leu	Tyr	Gly	Val	Pro	Val	Ser	Leu	Lys	Glu	Cys
							130	135			140				

Phe Ser Cys Lys Gly His Asp Ser Thr Leu Gly Leu Ser Arg Asn Gln
145 150 155 160

Gly Thr Pro Ala Glu Cys Asp Cys Val Val Val Gln Val Leu Lys Leu
165 170 175

Gln Gly Ala Val Pro Phe Val His Thr Asn Val Pro Gln Ser Met Phe
180 185 190

Ser Tyr Asp Cys Ser Asn Pro Leu Phe Gly Gln Thr Thr Asn Pro Trp
195 200 205

Met Ser Ser Lys Ser Pro Gly Gly Ser Ser Gly Gly Glu Gly Ala Leu
210 215 220

Ile Ala Ala Gly Gly Ser Pro Leu Gly Leu Gly Thr Asp Ile Gly Gly
225 230 235 240

Ser Ile Arg Phe Pro Ser Ala Phe Cys Gly Ile Cys Gly Ile Lys Pro
245 250 255

Thr Gly Asn Arg Ile Ser Lys Ser Gly Leu Lys Gly Ser Val Tyr Gly
260 265 270

Gln Val Ala Val Gln Leu Ser Val Gly Pro Met Ala Arg Asp Val Glu
275 280 285

Ser Leu Ala Leu Cys Leu Arg Ala Leu Leu Cys Glu Asp Met Phe Arg
290 295 300

Leu Asp Pro Thr Val Pro Pro Leu Pro Phe Asn Glu Glu Val Tyr Ala
305 310 315 320

Ser Ser Arg Pro Leu Arg Val Gly Tyr Tyr Glu Thr Asp Asn Tyr Thr
325 330 335

Met Pro Thr Pro Ala Met Arg Arg Ala Leu Leu Glu Thr Lys Arg Ser
340 345 350

Leu Glu Ala Ala Gly His Thr Leu Ile Pro Phe Leu Pro Ala Asn Ile
355 360 365

Pro His Ala Leu Glu Ala Leu Ser Thr Gly Gly Leu Phe Ser Asp Gly
370 375 380

Gly Lys Arg Leu Leu Gln Asn Phe Glu Gly Asp Tyr Val Asp Ser Cys
385 390 395 400

Leu Gly Asp Leu Ile Ser Ile Leu Arg Leu Pro Lys Trp Leu Lys Gly
405 410 415

Leu Leu Ala Phe Met Leu Arg Pro Leu Leu Pro Arg Leu Ala Gly Phe
420 425 430

Leu Ser Ser Leu Arg Pro Arg Ser Ala Gly Lys Leu Trp Glu Leu Gln
 435 440 445

His Glu Ile Glu Met Tyr Arg His Ser Val Ile Ala Gln Trp Arg Ala
 450 455 460

Leu Asp Leu Asp Val Val Leu Thr Pro Met Leu Ser Pro Ala Leu Asp
 465 470 475 480

Leu Asn Ala Pro Gly Lys Ala Thr Gly Ala Val Ser Tyr Thr Leu Leu
 485 490 495

Tyr Asn Cys Leu Asp Phe Pro Ala Gly Val Val Pro Val Thr Thr Val
 500 505 510

Thr Ala Glu Asp Glu Ala Gln Met Glu His Tyr Lys Gly Tyr Phe Gly
 515 520 525

Asp Ile Trp Asp Lys Val Val Gln Lys Ala Met Lys Arg Ser Val Gly
 530 535 540

Leu Pro Val Ala Val Gln Cys Val Ala Leu Pro Trp Gln Glu Glu Leu
 545 550 555 560

Cys Leu Arg Phe Met Arg Glu Val Glu Arg Leu Met Ala Pro Gly Arg
 565 570 575

Gln Pro Ser

<210> 3
<211> 1740
<212> DNA
<213> Mouse

<400> 3	
atggtgctga gcgaagtgtg gaccgcgtg tctggactct cgggggttttgc cctagcctgc	60
agcttgctgt cggccggcggt ggtcctgcga tggaccagga gccagaccgc cgggggcgcg	120
gtgaccaggg cgccggcagaa gcagcgagcc ggctggaga ccatggacaa ggcgggtgcag	180
cgcattccggc tgcagaatcc tgacctggat tcagaggcct tgctggctct gcccctgctc	240
caactggtagc agaagttaca gagtggggaa ctgtccccag aagctgtgct ctttacctac	300
ctggggaaagg cctggaaagt gaacaaaggg accaactgtg tgaccttcata tctgactgac	360
tgtgagactc agctgtccca ggccccacgg cagggcctgc tctatggcgt ccccgtagc	420
ctcaaggaat gcttcagcta caagggccat gcttccacac tgggcttaag tttgaacgag	480
ggtgtgacat cggagagtgta ctgtgtggtg gtgcaggtac tgaagctgca gggagctgtg	540
ccctttgtgc acaccaacgt cccccagtc atgctaagct atgactgcag taacccctc	600
tttggccaga ccatgaaccc gtggaagccc tccaagagtc caggaggttc ctcagggggt	660
gagggggctc tcattggatc tggaggctcc cctctgggtt taggcactga catcggcgcc	720

agcatccggc	tcc <u>cc</u> ttctgc	cttctgtggc	atctgtggcc	tcaaggctac	tgggaaccgc	780
ctcagcaaga	gtggcctgaa	gagctgtgtt	tatggacaga	cagcagtgc	gctttctgtt	840
ggccccatgg	cacgggatgt	ggatagcctg	gcattgtgc	tgaaagccct	actttgttag	900
gatttgttcc	gcttggactc	caccatcccc	cccttgcct	tcagggagga	gatctacaga	960
agttctcgac	cccttggtgt	ggatactat	gaaactgaca	actacaccat	gcccaactcca	1020
gccatgagga	gggctgtgat	ggagaccaag	cagagtctcg	aggctgtgg	ccacacgctg	1080
gtccccttct	taccaaacaa	cataccttat	gccctggagg	tcctgtcggc	aggtggctg	1140
ttcagtgatg	gtggctgctc	ttttctccaa	aacttcaaag	gctgactttgt	ggatccctgc	1200
ttgggggacc	tggctttagt	gctgaagctg	cccagggtgt	ttaaaaaact	gctgagcttc	1260
ctgctgaagc	ctctgtttcc	tcggctggca	gccttctca	acagtagtgc	tcctcggtca	1320
gccgaaaagc	tgtgggaaact	gcagcatgag	attgagatgt	atcgccagtc	cgtcattgcc	1380
cagtggaaagg	caatgaactt	ggacgtggtg	ctaacccttca	tgctgggtcc	tgctctggat	1440
ttgaacacac	cgggcagagc	cacagggct	atcagctaca	ctgttctcta	taactgcctg	1500
gacttccctg	cgggggtgtt	gcctgtcacc	actgtgaccg	ctgaggacga	tgcccagatg	1560
gaacactaca	aaggctactt	tggggatatg	tggacaaca	ttctgaagaa	ggccatgaaa	1620
aagggtata	gcctgcctgt	ggctgtgcag	tgcgtggctc	tgccctggca	ggaagagctg	1680
tgtctgcgg	tcatgcggg	ggtggAACGG	ctgatgaccc	ctgaaaagcg	gccatcttga	1740

<210> 4
<211> 579
<212> PRT
<213> Mouse

<400> 4

Met Val Leu Ser Glu Val Trp Thr Ala Leu Ser Gly Leu Ser Gly Val
1 5 10 15

Cys Leu Ala Cys Ser Leu Leu Ser Ala Ala Val Val Leu Arg Trp Thr
20 25 30

Arg Ser Gln Thr Ala Arg Gly Ala Val Thr Arg Ala Arg Gln Lys Gln
35 40 45

Arg Ala Gly Leu Glu Thr Met Asp Lys Ala Val Gln Arg Phe Arg Leu
50 55 60

Gln Asn Pro Asp Leu Asp Ser Glu Ala Leu Leu Ala Leu Pro Leu Leu
65 70 75 80

Gln Leu Val Gln Lys Leu Gln Ser Gly Glu Leu Ser Pro Glu Ala Val
85 90 95

Leu Phe Thr Tyr Leu Gly Lys Ala Trp Glu Val Asn Lys Gly Thr Asn
100 105 110

Cys Val Thr Ser Tyr Leu Thr Asp Cys Glu Thr Gln Leu Ser Gln Ala

115 120 125

Pro Arg Gln Gly Leu Leu Tyr Gly Val Pro Val Ser Leu Lys Glu Cys
130 135 140

Phe Ser Tyr Lys Gly His Ala Ser Thr Leu Gly Leu Ser Leu Asn Glu
145 150 155 160

Gly Val Thr Ser Glu Ser Asp Cys Val Val Gln Val Leu Lys Leu
165 170 175

Gln Gly Ala Val Pro Phe Val His Thr Asn Val Pro Gln Ser Met Leu
180 185 190

Ser Tyr Asp Cys Ser Asn Pro Leu Phe Gly Gln Thr Met Asn Pro Trp
195 200 205

Lys Pro Ser Lys Ser Pro Gly Gly Ser Ser Gly Glu Gly Ala Leu
210 215 220

Ile Gly Ser Gly Gly Ser Pro Leu Gly Leu Gly Thr Asp Ile Gly Gly
225 230 235 240

Ser Ile Arg Phe Pro Ser Ala Phe Cys Gly Ile Cys Gly Leu Lys Pro
245 250 255

Thr Gly Asn Arg Leu Ser Lys Ser Gly Leu Lys Ser Cys Val Tyr Gly
260 265 270

Gln Thr Ala Val Gln Leu Ser Val Gly Pro Met Ala Arg Asp Val Asp
275 280 285

Ser Leu Ala Leu Cys Met Lys Ala Leu Leu Cys Glu Asp Leu Phe Arg
290 295 300

Leu Asp Ser Thr Ile Pro Pro Leu Pro Phe Arg Glu Glu Ile Tyr Arg
305 310 315 320

Ser Ser Arg Pro Leu Arg Val Gly Tyr Tyr Glu Thr Asp Asn Tyr Thr
325 330 335

Met Pro Thr Pro Ala Met Arg Arg Ala Val Met Glu Thr Lys Gln Ser
340 345 350

Leu Glu Ala Ala Gly His Thr Leu Val Pro Phe Leu Pro Asn Asn Ile
355 360 365

Pro Tyr Ala Leu Glu Val Leu Ser Ala Gly Gly Leu Phe Ser Asp Gly
370 375 380

Gly Cys Ser Phe Leu Gln Asn Phe Lys Gly Asp Phe Val Asp Pro Cys
385 390 395 400

Leu Gly Asp Leu Val Leu Val Leu Lys Leu Pro Arg Trp Phe Lys Lys
 405 410 415

Leu Leu Ser Phe Leu Leu Lys Pro Leu Phe Pro Arg Leu Ala Ala Phe
 420 425 430

Leu Asn Ser Met Cys Pro Arg Ser Ala Glu Lys Leu Trp Glu Leu Gln
 435 440 445

His Glu Ile Glu Met Tyr Arg Gln Ser Val Ile Ala Gln Trp Lys Ala
 450 455 460

Met Asn Leu Asp Val Val Leu Thr Pro Met Leu Gly Pro Ala Leu Asp
 465 470 475 480

Leu Asn Thr Pro Gly Arg Ala Thr Gly Ala Ile Ser Tyr Thr Val Leu
 485 490 495

Tyr Asn Cys Leu Asp Phe Pro Ala Gly Val Val Pro Val Thr Thr Val
 500 505 510

Thr Ala Glu Asp Asp Ala Gln Met Glu His Tyr Lys Gly Tyr Phe Gly
 515 520 525

Asp Met Trp Asp Asn Ile Leu Lys Lys Gly Met Lys Lys Gly Ile Gly
 530 535 540

Leu Pro Val Ala Val Gln Cys Val Ala Leu Pro Trp Gln Glu Glu Leu
 545 550 555 560

Cys Leu Arg Phe Met Arg Glu Val Glu Arg Leu Met Thr Pro Glu Lys
 565 570 575

Arg Pro Ser

<210> 5
<211> 2472
<212> DNA
<213> rattus rattus

<400> 5	
ggtttgtcg agccgagttc tctcggtgg cggcggtctg caggagatca tggtgctgag	60
cgaagtgtgg accacgctgt ctggggtctc cggggtttgc ctgcctgca gcttgggttc	120
ggcgccggtg gtcctgcgt ggaccggcg ccagaaggcc cggggcgccgg cgaccaggc	180
gcggcagaag cagcgagcca gcctggagac catggacaag gcggtgcagc gttccggct	240
gcagaatcct gacctggact cggaggcctt gctgaccctg cccctactcc aactggtaca	300
gaagttacag agtggagagc tgtccccaga ggctgtgttc tttacttacc tggaaaggc	360
ctgggaagtg aacaaaaggga ccaactgcgt gaccccttat ctgaccgact gtgagactca	420
gctgtcccag gccccacggc agggcctgtctatggtgtc cctgtgagcc tcaaggaatg	480
cttcagctac aagggccacg actccacact gggcttgagc ctgaatgagg gcatgccatc	540

ggaatctgac	tgtgtgggg	tgcaagtgtt	gaagctgcag	ggagctgtgc	ccttttgtca	600
taccaatgtc	ccccagtcca	tgttaagctt	tgactgcagt	aaccctctct	ttggccagac	660
catgaaccca	tggaagtccct	ccaagagccc	aggaggttcc	tcagggggtg	agggggctct	720
cattggatct	ggaggttccc	ctctgggtt	aggcactgac	attggcggca	gcatcccggtt	780
cccttctgcc	ttctgcggca	tctgtggctt	caagcctact	ggcaaccgcc	tcagcaagag	840
tggcctgaag	ggctgtgtct	atggacagac	ggcagtgcag	ctttctctt	gccccatggc	900
ccggggatgtg	gagagcctgg	cgctatgcct	gaaagctcta	ctgtgtgagc	acttgttcac	960
cttggaccct	accgtgcctc	ccttgcctt	cagagaggag	gtctatagaa	gttcttagacc	1020
cctgcgtgtg	gggtactatg	agactgacaa	ctataccatg	cccagcccag	ctatgaggag	1080
ggctctgata	gagaccaagc	agagacttga	ggctgctggc	cacacgctga	ttcccttctt	1140
acccaacaac	ataccctacg	ccctggaggt	cctgtctgcg	ggcggcctgt	tcagtgacgg	1200
tggccgcagt	tttctccaaa	acttcaaagg	tgactttgtg	gatccctgct	tgggagacct	1260
gatcttaatt	ctgaggctgc	ccagctggtt	taaaaagactg	ctgagcctcc	tgctgaagcc	1320
tctgtttcct	cggctggcag	ccttctcaa	cagtatgcgt	cctcggcgt	ctgaaaaagct	1380
gtggaaaactg	cagcatgaga	ttgagatgta	tcgccagtct	gtgattgccc	agtggaaagc	1440
gatgaacttg	gatgtgctgc	tgacccccc	gttggccct	gctctggatt	tgaacacacc	1500
gggcagagcc	acaggggcta	tcagctacac	cgttctctac	aactgcctgg	acttccctgc	1560
gggggtggtg	cctgtcacca	ctgtgaccgc	cgaggacgat	gcccagatgg	aactctacaa	1620
aggctacttt	ggggatatatct	gggacatcat	cctgaagaag	gccatgaaaa	atagtgtcgg	1680
tctgcctgtg	gctgtgcagt	gcgtggctct	gccctggcag	gaagagctgt	gtctgaggtt	1740
catgcgggag	gtggaacagc	tgatgacccc	tcaaaagcag	ccatcgtgag	ggtcgttcat	1800
ccgccagctc	tggaggacct	aaggccatg	cgctgtgcac	tgtagcccc	tgtattcagg	1860
agccaccacc	cacgagggaa	cggccagcac	agggaaagagg	tgtctacctg	ccctccctg	1920
gactcctgca	gccacaacca	agtctggacc	ttccctcccc	ttatggtcta	ctttccatcc	1980
tgattccctg	ctttttatgg	cagccagcag	gaatgacgtg	ggccaaggat	caccaacatt	2040
caaaaacaat	gcgttatct	atttctggg	tatctccatt	agggccctgg	gaaccagagt	2100
gctggaaagg	ctgtccagac	cctccagagc	tggctgtaac	cacatcactc	tcctgctcca	2160
aaggccctct	agttctgtca	cccacaagat	agacacaggg	acatgtccct	ggcacttgac	2220
tcctgtcctt	cctttcttat	tcaaggatgac	cccagccttg	atggaccctg	cccctgcact	2280
tccttcctca	gtccacctct	ctgcccacac	gccctttta	tggctctct	atttggtg	2340
gagacaaggt	ttctctcagt	agccctggct	gtccaggacc	tcactctgta	gatgaggctg	2400
gctttcaact	cacaaggctg	cctgcctggg	tgctgggatt	aaaggcgtat	gccaccacaa	2460
agaaaaaaaaaa	aa					2472

<210> 6
<211> 579
<212> PRT

<213> rattus rattus

<400> 6

Met Val Leu Ser Glu Val Trp Thr Thr Leu Ser Gly Val Ser Gly Val
1 5 10 15

Cys Leu Ala Cys Ser. Leu Leu Ser Ala Ala Val Val Leu Arg Trp Thr
20 25 30

Gly Arg Gln Lys Ala Arg Gly Ala Ala Thr Arg Ala Arg Gln Lys Gln
35 40 45

Arg Ala Ser Leu Glu Thr Met Asp Lys Ala Val Gln Arg Phe Arg Leu
50 55 60

Gln Asn Pro Asp Leu Asp Ser Glu Ala Leu Leu Thr Leu Pro Leu Leu
65 70 75 80

Gln Leu Val Gln Lys Leu Gln Ser Gly Glu Leu Ser Pro Glu Ala Val
85 90 95

Phe Phe Thr Tyr Leu Gly Lys Ala Trp Glu Val Asn Lys Gly Thr Asn
100 105 110

Cys Val Thr Ser Tyr Leu Thr Asp Cys Glu Thr Gln Leu Ser Gln Ala
115 120 125

Pro Arg Gln Gly Leu Leu Tyr Gly Val Pro Val Ser Leu Lys Glu Cys
130 135 140

Phe Ser Tyr Lys Gly His Asp Ser Thr Leu Gly Leu Ser Leu Asn Glu
145 150 155 160

Gly Met Pro Ser Glu Ser Asp Cys Val Val Val Gln Val Leu Lys Leu
165 170 175

Gln Gly Ala Val Pro Phe Val His Thr Asn Val Pro Gln Ser Met Leu
180 185 190

Ser Phe Asp Cys Ser Asn Pro Leu Phe Gly Gln Thr Met Asn Pro Trp
195 200 205

Lys Ser Ser Lys Ser Pro Gly Gly Ser Ser Gly Gly Glu Gly Ala Leu
210 215 220

Ile Gly Ser Gly Gly Ser Pro Leu Gly Leu Gly Thr Asp Ile Gly Gly
225 230 235 240

Ser Ile Arg Phe Pro Ser Ala Phe Cys Gly Ile Cys Gly Leu Lys Pro
245 250 255

Thr Gly Asn Arg Leu Ser Lys Ser Gly Leu Lys Gly Cys Val Tyr Gly
260 265 270

Gln Thr Ala Val Gln Leu Ser Leu Gly Pro Met Ala Arg Asp Val Glu
275 280 285

Ser Leu Ala Leu Cys Leu Lys Ala Leu Leu Cys Glu His Leu Phe Thr
290 295 300 305

Leu Asp Pro Thr Val Pro Pro Leu Pro Phe Arg Glu Glu Val Tyr Arg
310 315 320

Ser Ser Arg Pro Leu Arg Val Gly Tyr Glu Thr Asp Asn Tyr Thr
325 330 335

Met Pro Ser Pro Ala Met Arg Arg Ala Leu Ile Glu Thr Lys Gln Arg
340 345 350

Leu Glu Ala Ala Gly His Thr Leu Ile Pro Phe Leu Pro Asn Asn Ile
355 360 365

Pro Tyr Ala Leu Glu Val Leu Ser Ala Gly Gly Leu Phe Ser Asp Gly
370 375 380

Gly Arg Ser Phe Leu Gln Asn Phe Lys Gly Asp Phe Val Asp Pro Cys
385 390 395 400

Leu Gly Asp Leu Ile Leu Ile Leu Arg Leu Pro Ser Trp Phe Lys Arg
405 410 415

Leu Leu Ser Leu Leu Leu Lys Pro Leu Phe Pro Arg Leu Ala Ala Phe
420 425 430

Leu Asn Ser Met Arg Pro Arg Ser Ala Glu Lys Leu Trp Lys Leu Gln
435 440 445

His Glu Ile Glu Met Tyr Arg Gln Ser Val Ile Ala Gln Trp Lys Ala
450 455 460

Met Asn Leu Asp Val Leu Leu Thr Pro Met Leu Gly Pro Ala Leu Asp
465 470 475 480

Leu Asn Thr Pro Gly Arg Ala Thr Gly Ala Ile Ser Tyr Thr Val Leu
485 490 495

Tyr Asn Cys Leu Asp Phe Pro Ala Gly Val Val Pro Val Thr Thr Val
500 505 510

Thr Ala Glu Asp Asp Ala Gln Met Glu Leu Tyr Lys Gly Tyr Phe Gly
515 520 525

Asp Ile Trp Asp Ile Ile Leu Lys Lys Ala Met Lys Asn Ser Val Gly
530 535 540

Leu Pro Val Ala Val Gln Cys Val Ala Leu Pro Trp Gln Glu Glu Leu
545 550 555 560

Cys Leu Arg Phe Met Arg Glu Val Glu Gln Leu Met Thr Pro Gln Lys
565 570 575

Gln Pro Ser

<210> 7
<211> 2063
<212> DNA
<213> homo sapiens

<400> 7
tgccggccgg taggcagcag caggctgaag ggatcatggt gcagtacgag ctgtggcccg 60
cgctgcctgg cgcctccggg gtcgcctgg cctgctgctt cgtggccggc gccgtggccc 120
tgcgcgtggc cgggcgccgg acggcgcggg gcgcgggtggt ccgggcgcga cagaagcagc 180
gagcgggcct ggagaacatg gacagggcgg cgcaagcgctt ccggctccag aaccaggacc 240
tggactcaga ggcgctgcta gccctgcccc tgcctcagct ggtgcagaag ttacacagta 300
gagagctggc ccctgaggcc gtgctttca cctatgtggg aaaggcctgg gaagtgaaca 360
aagggaccaa ctgtgtgacc tcctatctgg ctgactgtga gactcagctg tctcaggccc 420
caaggcaggg cctgctctat ggctccctg tgagcctcaa ggagtgcattt acctacaagg 480
gccaggactc cacgctggc ttgagcctga atgaagggtt gccggcggag tgcacagcg 540
tagtggtgca tgtgtgaag ctgcagggtg ccgtgcctt cgtgcacacc aatgttccac 600
agtccatgtt cagctatgac tgcaagtaacc ccctcttgg ccagaccgtg aaccatgga 660
agtccctcaa aagcccaggg ggctccctag ggggtgaagg ggccctcatc gggcttgag 720
gtctccctt gggcttaggc actgatatcg gaggcagcat ccgctccccc tcctccttct 780
gcggcatctg cggctcaag cccacaggaa accgcctcag caagagtggc ctgaagggt 840
gtgtctatgg acaggaggca gtgcgtctt ccgtggcccg catggcccg gacgtggaga 900
gcctggact gtgcctgcga gccctgtgt gcgaggacat gttccgttg gacccactg 960
tgcctccctt gccctcaga gaagagggtt acaccagctc tcagccctg cgtgtgggt 1020
actatgagac tgacaactat accatgcctt cccggccat gaggcgggca gtgtggaga 1080
ccaaacagag ctttgggtct gggggcaca cgctggttcc ttcttgcca agcaacatac 1140
cccatgtct ggagaccctg tcaacagggtt ggctttcag tgatggggc cacaccccttcc 1200
tacagaactt caaagggtat ttctgtggacc cctgcctggg ggacctggc tcaattctga 1260
.agcttccca atggctaaa ggactgctgg cttctgtgtt gaagcctctg ctgccaaggc 1320
tgtcagcttt cctcagcaac atgaagtctc gttcggctgg aaaactctgg gaactgcagc 1380
acgagatcga ggttaccgc aaaaccgtga ttgcccagtg gagggcgctg gacctggatg 1440
tgggtctgac ccccatgtct gcccctgtc tggacttggaa tgccccaggc agggccacag 1500
ggggcgtctcag ctacactatg ctgtacaact gcctggactt ccctgcaggg gtggtgccctg 1560
tcaccacggg gactgctgag gacgaggccc agatggaaaca ttacaggggc tactttgggg 1620
atatctggaa caagatgtctg cagaaggcga tgaagaagag tgtgggctg ccggtgcccg 1680

tgcagtgtgt ggctctgcc	tggcaagaag agttgtgtct	gcccgttcatg cgggaggtgg	1740
agcgactgat gaccctgaa aagcagtcat	cctgatggct ctggctccag aggacctgag	1800	
actcacactc tctgcagccc agcctagtca	gggcacagct gccctgctgc cacagcaagg	1860	
aatgtcctg catggggcag aggctccgt	gtcctctccc ccaacccct gcaagaagcg	1920	
ccgactccct gagtcggac ctccatccct	gctctggcc cctctttcg tcctgatccc	1980	
tccaccccca tgtggcagcc catggtatg	acataggcca aggcccaact aacagtcaag	2040	
aaacaaaaaaaaaaa	aaaaaaa aaa	2063	

<210> 8
<211> 579
<212> PRT
<213> homo sapiens

<400> 8

Met Val Gln Tyr Glu Leu Trp Ala Ala	Leu Pro Gly Ala Ser Gly Val		
1	5	10	15

Ala Leu Ala Cys Cys Phe Val Ala Ala	Ala Val Ala Leu Arg Trp Ser	
20	25	30

Gly Arg Arg Thr Ala Arg Gly Ala Val Val Arg Ala Arg Gln Lys Gln		
35	40	45

Arg Ala Gly Leu Glu Asn Met Asp Arg Ala Ala Gln Arg Phe Arg Leu		
50	55	60

Gln Asn Pro Asp Leu Asp Ser Glu Ala Leu Leu Ala Leu Pro Leu Pro			
65	70	75	80

Gln Leu Val Gln Lys Leu His Ser Arg Glu Leu Ala Pro Glu Ala Val		
85	90	95

Leu Phe Thr Tyr Val Gly Lys Ala Trp Glu Val Asn Lys Gly Thr Asn		
100	105	110

Cys Val Thr Ser Tyr Leu Ala Asp Cys Glu Thr Gln Leu Ser Gln Ala		
115	120	125

Pro Arg Gln Gly Leu Leu Tyr Gly Val Pro Val Ser Leu Lys Glu Cys		
130	135	140

Phe Thr Tyr Lys Gly Gln Asp Ser Thr Leu Gly Leu Ser Leu Asn Glu			
145	150	155	160

Gly Val Pro Ala Glu Cys Asp Ser Val Val Val His Val Leu Lys Leu		
165	170	175

Gln Gly Ala Val Pro Phe Val His Thr Asn Val Pro Gln Ser Met Phe		
180	185	190

Ser Tyr Asp Cys Ser Asn Pro Leu Phe Gly Gln Thr Val Asn Pro Trp
195 200 205

Lys Ser Ser Lys Ser Pro Gly Gly Ser Ser Gly Gly Glu Gly Ala Leu
210 215 220

Ile Gly Ser Gly Gly Ser Pro Leu Gly Leu Gly Thr Asp Ile Gly Gly
225 230 235 240

Ser Ile Arg Phe Pro Ser Ser Phe Cys Gly Ile Cys Gly Leu Lys Pro
245 250 255

Thr Gly Asn Arg Leu Ser Lys Ser Gly Leu Lys Gly Cys Val Tyr Gly
260 265 270

Gln Glu Ala Val Arg Leu Ser Val Gly Pro Met Ala Arg Asp Val Glu
275 280 285

Ser Leu Ala Leu Cys Leu Arg Ala Leu Leu Cys Glu Asp Met Phe Arg
290 295 300

Leu Asp Pro Thr Val Pro Pro Leu Pro Phe Arg Glu Glu Val Tyr Thr
305 310 315 320

Ser Ser Gln Pro Leu Arg Val Gly Tyr Tyr Glu Thr Asp Asn Tyr Thr
325 330 335

Met Pro Ser Pro Ala Met Arg Arg Ala Val Leu Glu Thr Lys Gln Ser
340 345 350

Leu Glu Ala Ala Gly His Thr Leu Val Pro Phe Leu Pro Ser Asn Ile
355 360 365

Pro His Ala Leu Glu Thr Leu Ser Thr Gly Gly Leu Phe Ser Asp Gly
370 375 380

Gly His Thr Phe Leu Gln Asn Phe Lys Gly Asp Phe Val Asp Pro Cys
385 390 395 400

Leu Gly Asp Leu Val Ser Ile Leu Lys Leu Pro Gln Trp Leu Lys Gly
405 410 415

Leu Leu Ala Phe Leu Val Lys Pro Leu Leu Pro Arg Leu Ser Ala Phe
420 425 430

Leu Ser Asn Met Lys Ser Arg Ser Ala Gly Lys Leu Trp Glu Leu Gln
435 440 445

His Glu Ile Glu Val Tyr Arg Lys Thr Val Ile Ala Gln Trp Arg Ala
450 455 460

Leu Asp Leu Asp Val Val Leu Thr Pro Met Leu Ala Pro Ala Leu Asp
465 470 475 480

Leu Asn Ala Pro Gly Arg Ala Thr Gly Ala Val Ser Tyr Thr Met Leu
485 490 495

Tyr Asn Cys Leu Asp Phe Pro Ala Gly Val Val Pro Val Thr Thr Val
500 505 510

Thr Ala Glu Asp Glu Ala Gln Met Glu His Tyr Arg Gly Tyr Phe Gly
515 520 525

Asp Ile Trp Asp Lys Met Leu Gln Lys Gly Met Lys Lys Ser Val Gly
530 535 540

Leu Pro Val Ala Val Gln Cys Val Ala Leu Pro Trp Gln Glu Glu Leu
545 550 555 560

Cys Leu Arg Phe Met Arg Glu Val Glu Arg Leu Met Thr Pro Glu Lys
565 570 575

Gln Ser Ser

CORRECTED VERSION

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date
6 May 2004 (06.05.2004)

PCT

(10) International Publication Number
WO 2004/037371 A2


- (51) International Patent Classification⁷: **B01D**
- (21) International Application Number: **PCT/US2003/033354**
- (22) International Filing Date: 21 October 2003 (21.10.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/420,065 21 October 2002 (21.10.2002) US
- (71) Applicant (*for all designated States except US*):
JANSSEN PHARMACEUTICA N.V. [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): BARBIER, Ann, Johanna [BE/US]; 7421 Eads Avenue, La Jolla, CA 92037
- (US). WILSON, Sandy, J. [US/US]; 10669 Carmel Mountain Road, San Diego, CA 92129 (US). MAZUR, Curt [US/US]; 943 Armada Terrace, San Diego, CA 92106 (US).
- (74) Agents: ELDERKIN, Dianne et al.; Woodcock Washburn LLP, One Liberty Place, 46th Floor, Philadelphia, PA 19103 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,

[Continued on next page]

- (54) Title: ASSAY FOR DETERMINING THE ACTIVITY OF FATTY ACID AMIDE HYDROLASE



WO 2004/037371 A2



- (57) Abstract: The invention provides methods of assaying fatty acid amide hydrolase (FAAH) activity adaptable for high throughput screening. The methods provide for separating a labeled substrate from at least one labeled hydrolysis product, the separation facilitating the quantification. The invention also provides methods of identifying a compound to be tested as an inhibitor or an activator of FAAH activity through the addition of the compound to be tested to a reaction mixture and comparison of the enzyme activity in the presence and absence of the compounds to be tested. The methods are adaptable for use in detecting altered FAAH activity in patients, for example, those at risk for *in vitro* fertilization failure, or at risk for, or suffering, addictions.



SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(15) **Information about Correction:**
see PCT Gazette No. 34/2004 of 19 August 2004, Section II

Published:

- *without international search report and to be republished
upon receipt of that report*

(48) **Date of publication of this corrected version:**

19 August 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.